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A B S T R A C T
Background
Survival rates have greatly improved as a result of more effective treatments for childhood cancer. Unfortunately the improved prognosis
has resulted in the occurrence of late, treatment-related complications. Liver complications are common during and soon after treatment
for childhood cancer. However, among long-term childhood cancer survivors the risk of hepatic late adverse effects is largely unknown.
To make informed decisions about future cancer treatment and follow-up policies it is important to know the risk of, and associated
risk factors for, hepatic late adverse effects.
Objectives
To evaluate the existing evidence on the association between antineoplastic treatment for childhood cancer and hepatic late adverse
effects.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, Issue 2), MEDLINE
(1966 to June 2009) and EMBASE (1980 to June 2009). In addition, we searched reference lists of relevant articles and conference
proceedings.
Selection criteria
All studies except case reports, case series and studies including less than 10 patients that examined the association between antineoplastic
treatment for childhood cancer (aged 18 years or less at diagnosis) and hepatic late adverse effects (one year or more after the end of
treatment).
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Data collection and analysis
Two review authors independently performed the study selection, risk of bias assessment and data extraction.
Main results
We identified 20 cohort studies investigating hepatic late adverse effects after antineoplastic treatment for childhood cancer. All studies
had methodological limitations. The prevalence of hepatic late adverse effects varied widely, between 0% and 84.2%. Selecting studies
where the outcome of hepatic late adverse effects was well defined as alanine aminotransferase (ALT) above the upper limit of normal
resulted in five studies. In this subgroup the prevalence of hepatic late adverse effects ranged from 8.0% to 52.8%, with follow-up
durations varying from one to 27 years after the end of treatment. A more stringent selection process using the outcome definition of
ALT as above twice the upper limit of normal resulted in three studies, with a prevalence ranging from 7.9% to 44.8%. Chronic viral
hepatitis was identified as a risk factor for hepatic late adverse effects in univariate analyses. It is unclear which specific antineoplastic
treatments increase the risk of hepatic late adverse effects
Authors’ conclusions
The prevalence of hepatic late adverse effects ranged from 7.9% to 52.8% when selecting studies with an adequate outcome definition.
It has not been established which childhood cancer treatments result in hepatic late adverse effects. There is a suggestion that chronic
viral hepatitis increases the risk of hepatic late adverse effects. More well-designed studies are needed to reliably evaluate the prevalence
of, and risk factors for, hepatic late adverse effects after antineoplastic treatment for childhood cancer.
P L A I N L A N G U A G E S U M M A R Y
Treatment-related late effects on the liver in survivors of childhood cancer
Advances in the treatment of childhood cancer over the last decades have greatly improved the survival rates. Unfortunately, the
improved prognosis has been accompanied by the occurrence of late, treatment-related complications. One of the adverse effects that
can occur due to treatment of childhood cancer is damage to the liver. Hepatic adverse effects are common both during and soon after
treatment. However, the evidence on adverse effects in the liver many years after treatment is still inconclusive. Liver injury as a result
of childhood cancer treatment is most often subclinical (asymptomatic). If liver disease becomes symptomatic, a person’s complaints
may include fatigue, jaundice, nausea, weight loss and abdominal pain. The development of future treatment and follow-up policies
should be based on high quality evidence on the risk of, and associated risk factors for, hepatic late adverse effects.
In this systematic review, 20 cohort studies examining hepatic late adverse effects after antineoplastic treatment for childhood cancer
were included. The authors found that 8% to 53% of the childhood cancer survivors developed hepatic late adverse effects after their
treatment. It is unclear which childhood cancer treatments increase the risk of hepatic late adverse effects. Childhood cancer survivors
with chronic viral hepatitis seemed to have an increased risk of hepatic late adverse effects. The quality of the evidence was however
limited. Therefore, more high quality research is needed.
B A C K G R O U N D
Survival rates have greatly improved as a result of more effective
treatments for childhood cancer. Today, most children diagnosed
with cancer are expected to become long-term cancer survivors
(Curry 2006). Five-year disease-free survival now reaches 80% in
Europe (Gatta 2009). Unfortunately, the improved prognosis has
been accompanied by the occurrence of late, treatment-related
complications. In two large cohort studies of childhood cancer
survivors nearly 75% experienced one or more late adverse effects
(Geenen 2007; Oeffinger 2006).
Liver complications are common during and soon after treatment
for childhood cancer (Field 2008). However, among long-term
childhood cancer survivors the prevalence of chronic liver disease,
like fibrosis and cirrhosis, is largely unknown. It has been sug-
gested that survivors of childhood cancer who received chemo-
therapy, particularly methotrexate, 6-mercaptopurine, 6-thiogua-
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nine, busulphan and dactinomycin; bone marrow transplantation
(BMT); radiotherapy involving the liver, including total body ir-
radiation (TBI); or hepatectomy are at risk for developing hepatic
late adverse effects (Bresters 2008; Castellino 2010;Dawson 2005;
King 2001). However the evidence has been inconclusive.
The aetiology of chronic liver disease following treatment for child-
hood cancer is complex as often more than one aetiologic fac-
tor is present. In addition to cancer treatment, other causes of
chronic liver disease are chronic viral hepatitis, veno-occlusive dis-
ease (VOD), graft-versus-host disease (GVHD), and iron overload
(Locasciulli 1997; Rizzo 2006; Strasser 1999). Regarding chronic
viral hepatitis, patients who were treated for childhood cancer be-
fore effective hepatitis C virus (HCV) donor screening was im-
plemented are especially at risk for transfusion-acquired HCV in-
fection. Childhood cancer survivors differ from other groups with
chronic viral hepatitis in that they acquired the infection at a young
age and were likely to have received immunosuppressive or hepa-
totoxic therapy (Fink 1993; Strickland 2000).
For better development of primary and secondary hepatic protec-
tive strategies in childhood cancer, more insight into the associ-
ation between cancer treatment and hepatic late adverse effects
is essential. Furthermore, for the follow-up of childhood cancer
survivors it is crucial to know the risk and associated risk factors so
that patients at greatest risk can be identified and adequate follow-
up protocols established to reduce the consequences of hepatic late
adverse effects. With increased survival duration after cancer, sur-
vivors are at risk for second malignancies and normal diseases of
aging which will require additional pharmacotherapy. This addi-
tional morbidity risk also underscores the need for understanding
the state of liver health in the long-term survivor of a childhood
cancer.
O B J E C T I V E S
To evaluate all the existing evidence on the association between
antineoplastic treatment (that is chemotherapy, radiotherapy in-
volving the liver, surgery involving the liver and BMT) for child-
hood cancer and hepatic late adverse effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All study designs except case reports, case series (that is description
of non-consecutive cases) and studies including less than 10 pa-
tients that examined the association between antineoplastic treat-
ment for childhood cancer and hepatic late adverse effects.
Types of participants
Childhood cancer survivors, diagnosed between the age of 0 and
18 years, who were at least one year after the end of their cancer
treatment. More than 50% of the study group should have been
diagnosed between the age of 0 and 18 years. In addition, more
than 50% of the study group should have been off treatment for
at least one year. Because the aim of this systematic review was
to evaluate the risk of, and associated risk factors for, hepatic late
adverse effects after antineoplastic treatment for childhood cancer,
we excluded studies in which the study population consisted solely
of childhood cancer survivors with chronic viral hepatitis. In this
way, it was possible to reliably evaluate risk factors for hepatic late
adverse effects after cancer treatment.
Types of interventions
Treatment with chemotherapy, radiotherapy involving the liver
(includingTBI), surgery involving the liver or BMT, or both. Liver
transplantations were excluded.
Types of outcome measures
Hepatic late adverse effects measured by liver enzymes (that
is alanine aminotransferase (ALT), glutamic pyruvic transami-
nase (SGPT) and aspartate aminotransferase (AST), glutamic ox-
aloacetic transaminase (SGOT) to investigate cellular liver injury,
and gamma-glutamyltransferase (GGT)) and alkaline phosphatase
(ALP) or bilirubin, or both, to investigate disturbances in bile ex-
cretion and biliary tract injury. In addition, measures of liver syn-
thetic function were included: coagulation times (prothrombin
time (PTT) or activated partial thromboplastin time (APTT)),
albumin or liver histology, or both. These clinically relevant out-
come measures were selected as recommended by an expert in the
field (BK). In this review we used the cut-off limit for normal and
abnormal liver enzyme values as specified by the authors of the
original studies.
Search methods for identification of studies
Electronic searches
The following electronic databases were searched: the Cochrane
Central Library of Controlled Trials (CENTRAL) (The Cochrane
Library 2009, Issue 2), MEDLINE (PubMed) (from 1945 to June
2009) and EMBASE (Ovid) (from 1980 to June 2009). The sen-
sitive search strategies used for MEDLINE, EMBASE and CEN-
TRAL are presented in Appendix 1, Appendix 2 and Appendix 3.
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Searching other resources
The reference lists of all relevant articles and reviews were screened
for additional references which were not registered in MED-
LINE, EMBASE or CENTRAL. We also scanned the conference
proceedings of the International Society of Paediatric Oncology
(SIOP) (from 2005 to 2009) electronically.
We did not impose language restrictions.
Data collection and analysis
Selection of studies
After performing the search strategy described previously, two re-
view authors independently selected studies that met the inclusion
criteria. Discrepancies between review authors were resolved by
consensus. If this was impossible, we achieved final resolution us-
ing a third-party arbitrator. We obtained the full text of any study
seemingly meeting the inclusion criteria on the grounds of the
title or abstract, or both, for closer inspection. We clearly stated
the details of our reasons for exclusion of any study considered for
this review.
Data extraction and management
Two review authors independently performed data extraction us-
ing standardised forms. The following data were extracted: study
design, original cohort, described study group, study group of in-
terest, study group with liver function testing, control group (if ap-
plicable), patient characteristics (including age, gender, body mass
index (BMI), tumour type, years of survival, acute liver disease
and hepatitis virus infection), cancer treatment (including chemo-
therapy, radiotherapy involving the liver, BMT and hepatectomy),
duration and completion of follow-up, hepatic late adverse effects
(including method of detection, definition and outcome measure)
and risk factors. In case of disagreement, a third review author was
consulted.
We defined cohort studies as studies in which a group of con-
secutive patients treated for childhood cancer was followed from
a similar well defined point in the course of the disease (x-year
survivors). The described study group could be the entire original
cohort of childhood cancer survivors or a subgroup of the original
cohort, based on well defined inclusion criteria.
The patients in the original cohort represent the whole group of
childhood cancer survivors. The described study group encom-
passes the childhood cancer survivors from the original cohort in-
cluded in the study. The study group of interest are the childhood
cancer survivors within the original cohort who received treatment
with a high potential for hepatic late adverse effects. Finally, the
study group with liver function testing are the childhood cancer
survivors who were assessed for hepatic late adverse effects as well.
Assessment of risk of bias in included studies
The assessment of risk of bias was based on earlier described
checklists for observational studies according to Evidence-Based
Medicine Criteria (Grimes 2002; Laupacis 1994). Two review au-
thors independently undertook the assessment of risk of bias of the
included studies, concerning the selection of the study group, the
follow-up and outcome assessments, and themethods used for risk
estimation. For evaluation of internal validity we assessed the risk
of selection bias, attrition bias, detection bias and confounding
that was present in the included studies. It included the following
items: representativeness of the study group, completeness of the
follow-up, blinding of the outcome assessors, and adjustment for
important confounding factors. For evaluation of external validity
we assessed the risk of reporting bias, which included the following
items: definition of the study group, reporting the length of fol-
low-up, objectiveness of the outcome definition and definition of
the analyses. The risk of bias assessment criteria for observational
studies are described in additional Table 1. Discrepancies between
review authors were resolved by consensus. In case of doubt, a
third review author was consulted.
Measures of treatment effect
Prevalence, cumulative incidence, mean difference, relative risk,
odds ratio, attributable risk, and other associated outcomes.
Assessment of heterogeneity
Heterogeneity was assessed both by visual inspection of the forest
plots and by a formal statistical test for heterogeneity, that is the I
2 statistic (I2 > 50% was considered as substantial heterogeneity)
(Higgins 2009). If there was evidence of substantial heterogeneity,
this was reported.
Assessment of reporting biases
We planned to construct a funnel plot to graphically ascertain the
existence of publicationbias. A rule of thumb is that tests for funnel
plot asymmetry are used only when there are at least 10 studies in
the meta-analysis. In the event of less than 10 studies the power
of the test is too low to distinguish chance from real asymmetry
(Higgins 2009). Given that none of the included studies in the
current analysis were pooled, we could not construct funnel plots.
Data synthesis
Data were entered into RevMan and analysed according to the
guidelines of the Cochrane Handbook (Higgins 2009). We used
a random-effects model throughout the review. All results are pre-
sented with the corresponding 95% confidence interval (95%CI).
We used the generic inverse variance function of RevMan to com-
bine the prevalences of hepatic late adverse effects. If pooling was
not possible, we provided descriptive results of these studies.
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Sensitivity analysis
We did not perform sensitivity analyses since pooling was not
possible for any of the outcomes. We did take into account the
risk of bias in studies included in this systematic review in the
interpretation of the results. We excluded studies with a high risk
of bias and studies for which the presence of bias was unclear to
compare the studies with a low risk of bias with the results of all
available studies.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
After performing the searches of the electronic databases ofMED-
LINE (PubMed), EMBASE (Ovid) and CENTRAL we identified
1703 references. Following initial screening of the titles and ab-
stracts, or both, we excluded 1572 which clearly did not meet all
pre-specified criteria for this systematic review. We obtained 131
articles in full text, of which seven met all the inclusion criteria.
For an Icelandic article it was unclear if the study was eligible for
inclusion. We are waiting for the translation. Therefore, this study
was added to the Characteristics of studies awaiting classification
table. The other 123 studies were not eligible for inclusion for the
reasons described in the Characteristics of excluded studies table.
After scanning the reference lists of relevant studies and reviews,
55 additional articles were retrieved formore detailed examination
and of which 13 met all the inclusion criteria. Forty-two studies
were added to the Characteristics of excluded studies table. By
scanning the conference proceedings of SIOP, we identified two
eligible studies that have not been published yet and are waiting
for further assessment (see the Characteristics of studies awaiting
classification table).
In total, our search identified 20 eligible studies examining the
association between antineoplastic treatment for childhood cancer
and hepatic late adverse effects. Characteristics of the included
studies are summarised below and their baseline characteristics
are described in the Characteristics of included studies table. It
should be noted, however, that there might be partial overlap in
included patients between the following studies: Locasciulli 1983,
Locasciulli 1985, Locasciulli 1991a and Locasciulli 1997a; Guido
1991 and Rossetti 1991.
The total number of patients included in the 20 identified
cohort studies who received treatment with a high poten-
tial for hepatic late adverse effects was 1590, ranging from
19 to 216 childhood cancer survivors per study. Thirteen
studies included patients diagnosed with leukaemia (that is
acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia
(AML), chronic myeloid leukaemia (CML) and acute non-
lymphoblastic leukaemia (ANLL)) (Aricò 1994; Bessho 1994;
Chotsampancharoen 2009; Guido 1991; Locasciulli 1983;
Locasciulli 1985; Locasciulli 1991a; Locasciulli 1997a; Matsuzaki
2001; Ratner 1986; Rossetti 1991; Vora 2006; Weber 1987); two
studies included patients with various forms of leukaemia and
non-malignant disease (Frisk 1998; Locasciulli 1997a); one study
with Wilms’ tumour, neuroblastoma and hepatoblastoma (Tefft
1970); one study with hepatoblastoma (Stringer 1995); one study
with various forms of leukaemia, benign haematological diseases,
immunological diseases and other inborn errors (Bresters 2008);
one study with Wilms’ tumour (Jagt 2009); and one study with
various tumours (Ballauff 1999).
In 19 of the 20 studies patients were treated with chemotherapy;
in one study it was unclear whether the patients received chemo-
therapy (Chotsampancharoen 2009). In 16 studies the type of
chemotherapy was mentioned, which varied considerably across
the studies (Bessho 1994; Bresters 2008; Frisk 1998; Guido 1991;
Jagt 2009; Locasciulli 1983; Locasciulli 1985; Locasciulli 1997b;
Matsuzaki 2001; Ratner 1986; Rossetti 1991; Stringer 1995; Tefft
1970; Vora 2006;Weber 1987). Seven studies mentioned the che-
motherapy dose according to the treatment protocol, which var-
ied widely (Bessho 1994; Jagt 2009; Locasciulli 1997b; Matsuzaki
2001; Stringer 1995; Vora 2006; Weber 1987). For all but one
study (Bessho 1994), the dose actually received by the patients
was unclear. Seven of the 20 studies reported whether the pa-
tients were treated with radiotherapy involving the liver (Bresters
2008; Chotsampancharoen 2009; Frisk 1998; Locasciulli 1997b;
Matsuzaki 2001; Stringer 1995; Tefft 1970) of which six studies
included patients who received radiotherapy involving the liver
(Bresters 2008; Chotsampancharoen 2009; Frisk 1998; Locasciulli
1997b; Stringer 1995; Tefft 1970). Four studies mentioned the
radiotherapy field and dose, which varied from 7.5 to 14.4 Gy
TBI (Chotsampancharoen 2009; Frisk 1998; Locasciulli 1997b)
and from less than 25 Gy to more than 35 Gy liver irradiation
(Tefft 1970). Two studies included patients treated with a hepatec-
tomy (Stringer 1995; Tefft 1970). Moreover, five studies included
patients treated with BMT (Bresters 2008; Chotsampancharoen
2009; Frisk 1998; Locasciulli 1991a; Locasciulli 1997b).
Eleven studies mentioned the age at diagnosis, which ranged
from 0.0 to 19.0 years (Bessho 1994; Guido 1991; Jagt 2009;
Locasciulli 1983; Locasciulli 1985; Locasciulli 1991a; Locasciulli
1997a; Stringer 1995; Tefft 1970; Vora 2006; Weber 1987). The
age at follow-up was reported by four studies (Aricò 1994; Ballauff
1999; Bessho 1994; Rossetti 1991) and ranged from 2.5 to 26.0
years. All but two studies (Ratner 1986; Vora 2006) mentioned
the gender of the included patients. The percentage of females in
these studies varied between 34% and 55%.
For the 18 studies that reported follow-up duration, the mini-
mum andmaximum duration varied widely from 0.0 to 13.0 years
minimal and 4.0 to 27.0 years maximal after the end of treat-
ment (Aricò 1994; Ballauff 1999; Bessho 1994; Bresters 2008;
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Chotsampancharoen 2009; Frisk 1998; Guido 1991; Locasciulli
1983; Locasciulli 1985; Locasciulli 1991a; Locasciulli 1997a;
Locasciulli 1997b; Ratner 1986; Rossetti 1991; Stringer 1995;
Tefft 1970; Vora 2006; Weber 1987). The median reported fol-
low-up duration also showed variation, ranging from 2.0 to 17.0
years after the end of treatment.
In the included studies, hepatic late adverse effects were variably
defined using ALT, AST, GGT, ALP, bilirubin and PTT. Fourteen
studies defined hepatic late adverse effects by abnormal values of
serum ALT or AST, or both (Aricò 1994; Bessho 1994; Bresters
2008; Chotsampancharoen 2009; Guido 1991; Locasciulli 1983;
Locasciulli 1985; Locasciulli 1991a; Locasciulli 1997a; Locasciulli
1997b; Matsuzaki 2001; Ratner 1986; Rossetti 1991; Vora 2006);
five studies defined hepatic late adverse effects by combined mea-
surements of ALT, AST, bilirubin, GGT, ALP or PTT, or both
(Ballauff 1999; Frisk 1998; Jagt 2009; Tefft 1970; Weber 1987);
and for one study it was unclear which biochemical liver function
tests were used (Stringer 1995). In 12 studies the upper limits of
normal were described (Aricò 1994; Bessho 1994; Bresters 2008;
Jagt 2009; Locasciulli 1983; Locasciulli 1985; Locasciulli 1991a;
Locasciulli 1997a; Locasciulli 1997b; Ratner 1986; Rossetti 1991;
Weber 1987): of which six studies defined hepatic late adverse
effects as ALT or AST, or both, above the upper limit of nor-
mal (Aricò 1994; Bessho 1994; Bresters 2008; Locasciulli 1991a;
Locasciulli 1997a; Locasciulli 1997b); three studies as ALT or
AST, or both, above two times the upper limit of normal (Bresters
2008; Ratner 1986; Rossetti 1991); two studies as ALT or AST,
or both, above three times the upper limit of normal (Locasciulli
1983; Locasciulli 1985); one study as ALT, AST, GGT and ALP
above the upper limit of normal (Jagt 2009); and one study as
ALT, bilirubin and ALP above the upper limit of normal (Weber
1987). In three studies liver biopsies were performed in a selected
group of patients (Locasciulli 1997a; Ratner 1986; Vora 2006).
Risk of bias in included studies
Data on the risk of bias in the 20 cohort studies are described in the
Characteristics of included studies table and are shown in Figure
1. All studies were found to have methodological limitations.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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For evaluation of internal validity we assessed the risk of selection
bias, attrition bias, detection bias and confounding present in the
included studies.
In five of the 20 studies the described study group consisted of the
entire original cohort of childhood cancer survivors (Aricò 1994;
Ballauff 1999; Frisk 1998; Locasciulli 1997b; Stringer 1995). Four
studies described a subgroup of the original cohort (Bresters 2008;
Chotsampancharoen 2009; Locasciulli 1991a; Locasciulli 1997a).
In one study this subgroup consisted ofmore than 90%of the orig-
inal cohort (Locasciulli 1997a). In the other three studies this sub-
group neither consisted of more than 90% of the original cohort
nor was it a random sample with respect to the cancer treatment
(Bresters 2008; Chotsampancharoen 2009; Locasciulli 1991a).
For 11 studies the number of patients in the original cohort was
not mentioned (Bessho 1994; Guido 1991; Jagt 2009; Locasciulli
1983; Locasciulli 1985; Matsuzaki 2001; Ratner 1986; Rossetti
1991; Tefft 1970; Vora 2006; Weber 1987). For these studies it
was unclear whether the described study group consisted of more
than 90% of the original cohort of childhood cancer survivors or
whether it was a random sample with respect to the cancer treat-
ment. Hence, in six of the 20 studies (30.0%) the study group was
representative. So, selection bias could not be ruled out in 70.0%
of the included studies.
Seventeen studies (85.0%) had an adequate follow-up (based on
> 60% of the study group of interest) (Aricò 1994; Ballauff 1999;
Bessho 1994; Bresters 2008; Frisk 1998; Jagt 2009; Locasciulli
1983; Locasciulli 1991a; Locasciulli 1997a; Locasciulli 1997b;
Matsuzaki 2001; Ratner 1986; Rossetti 1991; Stringer 1995; Tefft
1970; Vora 2006; Weber 1987), of which 12 studies assessed the
outcome for more than 90% of the study group of interest (Aricò
1994; Ballauff 1999; Bessho 1994; Bresters 2008; Frisk 1998;
Locasciulli 1991a; Locasciulli 1997a; Locasciulli 1997b; Ratner
1986; Stringer 1995; Vora 2006; Weber 1987). Two studies as-
sessed the outcome for less than 60% of the study group of inter-
est and thus were scored as having incomplete follow-up (Guido
1991; Locasciulli 1985), and for one study the completion of fol-
low-upwas unclear (Chotsampancharoen 2009).Hence, there was
a risk of attrition bias in three of the 20 studies (15.0%).
Detection bias could not be ascertained as none of the studies
reported that liver outcome was assessed by an investigator blinded
to the treatment status of the participants.
Nine studies assessed possible risk factors for the development of
hepatic late adverse effects (Aricò 1994; Ballauff 1999; Bresters
2008; Chotsampancharoen 2009; Locasciulli 1983; Locasciulli
1991a; Locasciulli 1997a; Rossetti 1991; Tefft 1970). These stud-
ies only conducted univariate analyses and thus did not adjust for
important confounders. So, there was a risk of confounding in
100% of the studies which assessed possible risk factors.
For evaluation of external validity we assessed the risk of reporting
bias present in the included studies.
In 10 of the 20 studies (50.0%) the study group was well de-
fined in terms of antineoplastic therapy exposure and chronic viral
hepatitis (Bessho 1994; Bresters 2008; Frisk 1998; Guido 1991;
Locasciulli 1983; Locasciulli 1985; Locasciulli 1997b; Matsuzaki
2001; Ratner 1986; Rossetti 1991). The other 10 studies failed
to mention the type of chemotherapy (Aricò 1994; Ballauff 1999;
Locasciulli 1991a; Locasciulli 1997a) or the number of partici-
pants with chronic viral hepatitis (Chotsampancharoen 2009; Jagt
2009; Stringer 1995; Tefft 1970; Vora 2006; Weber 1987).
Eighteen studies (90.0%) reported the length of follow-up and
therefore had a well defined follow-up (Aricò 1994; Ballauff
1999; Bessho 1994; Bresters 2008; Chotsampancharoen 2009;
Frisk 1998; Guido 1991; Locasciulli 1983; Locasciulli 1985;
Locasciulli 1991a; Locasciulli 1997a; Locasciulli 1997b; Ratner
1986; Rossetti 1991; Stringer 1995; Tefft 1970; Vora 2006;Weber
1987).
In 12 studies the upper limits of normal for the liver function
tests that were used were described (Aricò 1994; Bessho 1994;
Bresters 2008; Jagt 2009; Locasciulli 1983; Locasciulli 1985;
Locasciulli 1991a; Locasciulli 1997a; Locasciulli 1997b; Ratner
1986; Rossetti 1991;Weber 1987). The other studies did notmen-
tion the upper limits of normal. So 12 of the 20 studies (60.0%)
had a well defined outcome.
Nine studies assessed possible risk factors for the development of
hepatic late adverse effects, all of which had a well defined risk
estimation (100%) (Aricò 1994; Ballauff 1999; Bresters 2008;
Chotsampancharoen 2009; Locasciulli 1983; Locasciulli 1991a;
Locasciulli 1997a; Rossetti 1991; Tefft 1970).
Hence, reporting bias could not be ruled out in up to 50.0% of
the included studies.
Effects of interventions
Prevalence of hepatic late adverse effects
The prevalence of hepatic late adverse effects as measured by liver
enzymes, bilirubin or coagulation times was reported in all but
one study (Chotsampancharoen 2009) and varied widely between
0% and 84.2% (see Characteristics of included studies). However,
five studies estimated the prevalence of hepatic late adverse effects
in a selected group of patients who were diagnosed with abnormal
liver function during or soon after the cancer treatment (Guido
1991; Locasciulli 1983; Locasciulli 1985; Locasciulli 1991a; Vora
2006). Excluding these studies resulted in a reported prevalence
of 0% to 58.0%.
Furthermore, hepatic late adverse effects were defined using differ-
ent liver function tests with varying cut-off limits. When selecting
studies with a well defined outcome, that is if the upper limits of
normal for the liver function tests were described in the defini-
tion of hepatic late adverse effects, nine studies remained (Aricò
1994; Bessho 1994; Bresters 2008; Jagt 2009; Locasciulli 1997a;
Locasciulli 1997b; Ratner 1986; Rossetti 1991;Weber 1987). Five
studies defined hepatic late adverse effects as ALT above the up-
per limit of normal (Aricò 1994; Bessho 1994; Bresters 2008;
Locasciulli 1997a; Locasciulli 1997b). The prevalence ranged from
8.0% to 52.8% (see Figure 2). Because unexplained heterogene-
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ity was detected (I2 = 86%) we were not able to pool the results
of these studies. The cancer treatment varied across the studies.
In all five studies the included patients were treated with chemo-
therapy. The chemotherapy regimens varied considerably. In two
studies it was reported that patients were also treated with TBI and
BMT (Bresters 2008; Locasciulli 1997b). In these two studies the
prevalence of hepatic late adverse effects was 24.5% and 52.8%,
respectively. Selecting studies in which a considerable proportion
of the patients had a chronic viral hepatitis resulted in three stud-
ies with a prevalence ranging from 21.6% to 52.8% (Aricò 1994;
Locasciulli 1997a; Locasciulli 1997b). Although other potential
sources of heterogeneity (that is risk of bias present in the studies,
age at diagnosis, follow-up duration, gender, acute liver morbid-
ity) also varied across these studies, they could not explain the
variation in the prevalence of hepatic late adverse effects.
Figure 2. Forest plot of comparison: 1 Prevalence of hepatic late adverse effects, outcome: 1.1 Prevalence
of hepatic late adverse effects in studies with an outcome definition of ALT above upper limit of normal.
Three studies defined hepatic late adverse effects as ALT above
two times the upper limit of normal (Bresters 2008; Ratner 1986;
Rossetti 1991). The prevalence ranged from 7.9% to 44.8% (see
Figure 3). Heterogeneity was also detected in this analysis (I2 =
96%). Patients included in the studies of Ratner 1986 (23.1%)
and Rossetti 1991 (44.8%) received comparable chemotherapy
regimens, that is vincristine, 6-mercaptopurine, methotrexate, as-
paraginase, cyclophosphamide, daunorubicin, hydroxyurea and
asparaginase. The treatment received by patients included in the
study of Bresters 2008 (7.9%) consisted of BMT, TBI, tho-
raco-abdominal irradiation (TAI), cyclophosphamide and busul-
phan. Chronic viral hepatitis could partly explain the variation in
the prevalence reported in Rossetti 1991 (44.8%), Ratner 1986
(23.1%) and Bresters 2008 (7.9%) with infection rates of 62.5%
(HBV), 12.8% (HBV) and 2.1% (HCV), respectively. In addi-
tion, the follow-up duration of patients included in the study of
Rossetti 1991 was longer (4 to 20 years after diagnosis) than the
follow-up duration in Ratner 1986 (1 to 8 years after the end of
treatment) and Bresters 2008 (2 years after BMT). There were no
differences in the risk of bias present in these studies.
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Figure 3. Forest plot of comparison: 1 Prevalence of hepatic late adverse effects, outcome: 1.2 Prevalence
of hepatic late adverse effects in studies with an outcome definition of ALT above twice upper limit of normal.
Because hepatic late adverse effects in the studies of Jagt 2009 and
Weber 1987 were defined using different assessment methods, we
were not able to combine the results of these two studies.
In three studies, liver biopsies were performed to evaluate hep-
atic late adverse effects in two, three and 10 patients, respectively
(Locasciulli 1997a; Ratner 1986; Vora 2006). All liver biopsies
were performed on clinical indication: persistent high ALT levels
(Locasciulli 1997a), chronic HBV infection (Ratner 1986) and
splenomegaly during and soon after chemotherapy (Vora 2006).
Patients were diagnosed with either chronic persistent hepatitis,
chronic lobular hepatitis, cirrhosis, portal fibrosis or nodular re-
generative hyperplasia.
Risk factors for hepatic late adverse effects
Nine studies investigated possible risk factors for hepatic late
adverse effects (Aricò 1994; Ballauff 1999; Bresters 2008;
Chotsampancharoen 2009; Locasciulli 1983; Locasciulli 1991a;
Locasciulli 1997a; Rossetti 1991; Tefft 1970). Chronic viral hep-
atitis (HCV,HBV,HBV-HDVco-infection) (Aricò 1994; Ballauff
1999; Locasciulli 1983; Locasciulli 1991a; Locasciulli 1997a;
Rossetti 1991), older age at haematopoietic stem cell transplanta-
tion (HSCT), diagnosis of a benign haematological disease, gen-
der, HSCT donor type (matched sibling donor, other), stem cell
source, conditioning regimen (cyclophosphamide with total body
irradiation (TBI) or thoraco-abdominal irradiation (TAI), cyclo-
phosphamide with busulphan, other), early post-transplant mor-
bidity (viral reactivation, VOD, acute GVHD) (Bresters 2008),
higher radiotherapy dose, and radiotherapy field (right lobe, left
lobe, entire liver, remaining liver) (Tefft 1970) were investigated
as possible risk factors for hepatic late adverse effects in univariate
analyses. There is a suggestion that chronic viral hepatitis increases
the risk of hepatic late adverse effects. However, the identification
of other risk factors has not been univocal across all studies (see
Characteristics of included studies and additional Table 2).
D I S C U S S I O N
In this review all available evidence on the association and risk of
hepatic late adverse effects after treatment for childhood cancer
was critically evaluated among 20 studies that met the inclusion
criteria. The reported prevalence of hepatic late adverse effects var-
ied considerably, between 0% and 84.2%. Part of this wide range
could be explained by the variation in outcome definition. Select-
ing studies where the outcome of hepatic late adverse effects was
well defined as ALT above the upper limit of normal resulted in
five studies. In this subgroup the prevalence of hepatic late ad-
verse effects ranged from 8.0% to 52.8%. A more stringent selec-
tion using an outcome definition of ALT above twice the upper
limit of normal resulted in three studies, with a prevalence rang-
ing from 7.9% to 44.8%. There is some suggestion that chronic
viral hepatitis could explain a part of this variation. There is no
clarity regarding which paediatric patients are at the greatest risk
of developing hepatic late adverse effects since no study evaluated
risk factors by multivariate analysis. However, there is a suggestion
from univariate analyses that chronic viral hepatitis increases the
risk of hepatic late adverse effects. The studies showed that even
many years after the end of treatment (13 to 27 years) elevated
liver transaminases, which indicate liver injury, were still detected.
Since none of the studies investigated the longitudinal develop-
ment of hepatic late adverse effects many years after treatment, it
is unclear if liver function improves or deteriorates over time.
From previous research it is known that methotrexate, 6-mercap-
topurine, 6-thioguanine, busulphan and dactinomycin increase
the risk of liver toxicity during or soon after cancer treatment (Field
2008; King 2001). It has been speculative that these chemothera-
peutics also increase the risk of hepatic late adverse effects. In the
current systematic review, however, none of the included studies
investigated the association between individual chemotherapeutic
agents and hepatic late adverse effects. There was a great diversity
in antineoplastic treatment among the participants in the indi-
vidual studies, so it was impossible to compare the effects of spe-
cific chemotherapeutics from the included studies. Hence, despite
the clear association between certain chemotherapeutic agents and
acute transaminase elevation, veno-occlusive disease (VOD) and
synthetic liver dysfunction (Field 2008; King 2001) the evidence
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for an increased risk of hepatic late adverse effects after treatment
with methotrexate, 6-mercaptopurine, 6-thioguanine, busulphan
or dactinomycin is limited.
Moreover, only one included study investigated the association
between radiotherapy to the liver and hepatic late adverse effects
(Tefft 1970). The study found that 58% of the patients had ab-
normal liver function tests at a mean follow-up of four years after
the end of treatment. The majority of patients were treated with
a liver irradiation dose of 25 Gy or more. Studies investigating
the association between radiotherapy to the liver and acute hepa-
totoxicity showed that the risk increased with radiation dose and
volume, younger age at treatment and prior partial hepatectomy
(Hudson 2005). Tefft 1970, however, did not show that a higher
radiotherapy dose is a risk factor for hepatic late adverse effects.
Chronic HBV and HCV infection were identified in six studies as
risk factors for hepatic late adverse effects, identified in univariate
analyses only. AcuteHBV infection in children has a variable clini-
cal course ranging from asymptomatic state to fulminant hepatitis,
with the rate of chronic infection ranging from 90% in neonates
to 1% to 5% in adolescents (Kurbegov 2009). Acute infection
with HCV tends to cause mild hepatitis, yet chronic infection
occurs in approximately 80% of patients (Villano 1999). When
chronically infected with HBV or HCV, patients are at risk for
liver-related morbidity and mortality from cirrhosis or hepatocel-
lular carcinoma. In a study of Castellino 2004, which investigated
the long-term outcomes of chronic HCV infection among sur-
vivors of childhood cancer, it was shown that at a median follow-
up of 12.4 years 28.8% of patients had developed mild fibrosis,
35.6% moderate fibrosis and 13.6% cirrhosis. This study was ex-
cluded from this systematic review because the study population
consisted solely of hepatitis virus infected childhood cancer sur-
vivors. It should be noted, however, that the importance of chronic
HCV infection among childhood cancer survivors is declining as
the global prevalence of HCV has dramatically decreased since
the introduction of effective screening of blood products in 1993
(Hudson 2005). Other reported risk factors were iron overload,
older age at haematopoietic stem cell transplantation (HSCT) and
the diagnosis of a benign haematological disease; although none
of the studies conducted multivariate analyses with adjustment
for important prognostic factors and follow-up. Results from uni-
variate analyses that do not take possible confounding factors into
account may lead to an overestimation of the prognostic influ-
ence of a single variable. Consequently, the results of these studies
must be interpreted with caution. No studies exist in which the
association between VOD or graft-versus-host disease (GVHD)
and hepatic late adverse effects was evaluated. In addition, none
of the studies in this systematic review included a control group. A
control group would have allowed us to separate out the effects of
important risk factors in order to determine the level of causation.
Liver histology is the current gold standard for diagnosing liver
damage but is applied conservatively in paediatric patients due to
the invasive nature of the test (Saleh 2007). Since only three stud-
ies performed liver biopsies, in a selected group of patients with
clinical indications, we were not able to analyse histologically de-
termined hepatic late adverse effects. Consequently, we had to fo-
cus on hepatic injury defined by elevated liver enzymes, especially
serum ALT level. Although ALT is produced by other organs, it
is found mainly in hepatocytes and is considered to be the most
reliable and sensitive single marker of acute or subacute liver injury
(Kim 2008). Recently Ruhl 2009 investigated whether elevated
ALT levels were associated with an increased risk of all-cause and
disease-specific mortality among 14,950 adults from the US pop-
ulation. Although elevated ALT was not associated with all-cause
mortality, it did relate to deaths from liver disease. An elevation in
ALT was associated with a more than eight-fold increased risk of
cause-specific mortality from liver disease. There is, however, still
some doubt about the validity of serum ALT as a marker of liver
disease. Elevated ALT can be asymptomatic and does not always
progress to liver failure or cirrhosis. Also, especially in the case of
chronic HCV infection, normal ALT levels have been found while
having mild liver abnormalities (Field 2008; Kim 2008). There-
fore, it is difficult to judge the exact clinical consequence of hepatic
late adverse effects as measured in this systematic review. Other
parameters which are frequently used for liver function testing are
ALP, GGT, bilirubin and coagulation times (PTT and APTT).
Because the studies included in this systematic review mainly re-
ported ALT levels it was impossible to draw any conclusions on
other measures of liver function and their relation to long-term
liver health in childhood cancer survivors.
After assessing the risk of bias of the included studies, which in-
cluded both the internal and external validity, it was obvious that
all studies had methodological limitations. However, it should be
noted that this assessment focused only on the evaluation of the
prevalence of hepatic late adverse effects. Therefore, the quality of
the included studies was only judged regarding these items.
The internal validity gives an indication of the bias present in a
study and thus how valid the results of a study are. There is a 70%
risk of selection bias in studies included in this systematic review.
This leads to concern that an overestimation of the prevalence
of hepatic late adverse effects exists if patients with a higher risk
profile were selected for the study, and an underestimation if pa-
tients with a lower risk profile were selected. In addition, the small
risk of attrition bias (15%) may lead to an overestimation of the
prevalence of hepatic late adverse effects if patients lost to follow-
up are in better health than those still under medical surveillance.
Conversely, it will lead to an underestimation if patients lost to
follow-up are more likely to be suffering from hepatic late adverse
effects, for example because they were more frequently unable to
complete the follow-up schedule of the study. Finally, there is also
a risk of detection bias. This can lead to an overestimation of the
prevalence of hepatic late adverse effects since knowledge of prog-
nostic factors can increase the possibility of classifying patients as
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having hepatic late adverse effects. However, because the outcome
is defined by absolute laboratory values and can be interpreted
objectively, blinding of the outcome assessor is of less importance
in this systematic review.
The external validity of a study indicates how well the results
of the study could be extrapolated to individual patients. There
is a moderate risk of reporting bias in studies included in this
systematic review. Because the study group was not well defined
in half of the included studies, and only a small majority used an
objective and precise outcome definition, it is difficult to interpret
the results correctly. Although most of the studies reported the
length of follow-up, the minimum and maximum duration varied
widely, from 0.0 to 13.0 years minimal and 4.0 to 27.0 years
maximal after the end of treatment. With short follow-up, it is
possible that the injury to the liver may be transient and reversible.
With longer follow-up, more patients will be at risk for hepatic late
adverse effects. However, it is not clear whether treatment-related
increased risks of hepatic late adverse effects will continue to be
raised with more prolonged follow-up, or that the risk will level
off or even decrease at some point of time. Therefore, cautious
interpretation of the results is needed when the study findings are
related to individual patients.
Variation in the studies that evaluate the prevalence of hepatic late
adverse effects could also be explained by other factors. Differences
in the prevalence of hepatic late adverse effects could be a reflection
of different risk profiles in the study population. Factors such as
chemotherapy type and dose, co-treatment with other hepatotoxic
drugs, age at diagnosis and age at follow-up varied considerably
across the studies, which may explain the variation in the preva-
lence. Moreover, it should be noted that the prevalence of chronic
HBV and HCV infection differ between countries and is based
on the era of cancer diagnosis (Hudson 2005). In Mediterranean
countries chronic viral hepatitis is more endemic (Baldo 2008) so
patients who received blood transfusions in these countries were
at higher risk for chronic HBV or HCV infections.
In conclusion, this systematic review showed that the prevalence
of hepatic late adverse effects ranged from 7.9% to 52.8% when
selecting studies with an adequate outcome definition. It has not
been established which childhood cancer treatments result in hep-
atic late adverse effects since most studies had limited sample sizes
(that is power) to evaluate the role of independent treatment-re-
lated risk factors by multivariate analysis. There is a suggestion
that chronic viral hepatitis increases the risk of hepatic late adverse
effects in childhood cancer survivors.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review shows that childhood cancer survivors are
at risk for hepatic late adverse effects defined as ALT above the
upper limit of normal. Evaluation of serum ALT level could be
helpful to screen early for hepatic late adverse effects. Abnormali-
ties should initiate additional evaluation and measurement to pre-
vent any further damage. However, recommendations about the
time interval of evaluation, groups of survivors inwhich evaluation
should be performed and the importance of other tests cannot be
made based on current evidence. To keep in mind, no evidence of
effect does not mean evidence of no effect. As more data become
available, clinicians will be able to make better-informed decisions
regarding the treatment of future childhood cancer patients and
to develop targeted follow-up programs for survivors. Since liver
disease can be indolent, it seems rational that counselling should
be provided regarding preventive behaviours like avoidance of al-
cohol, immunization against hepatitis A and B, and cautious use
of alternative therapies that have a risk of liver injury.
Implications for research
All studies showed methodological limitations. This underscores
the need for well-designed studies which reliably evaluate the
prevalence of hepatic late adverse effects after antineoplastic treat-
ment for childhood cancer in a prospective multicentre approach;
and the influence of risk factors such as different chemotherapeu-
tic drugs, chronic viral hepatitis, steatosis, VOD, iron overload
and GVHD. Survivors of haematopoietic stem cell transplant are
likely to be a highly vulnerable group that warrants study in this
area as well. Since many of the studies are quite dated and the
epidemiology of chronic viral hepatitis has changed, more cur-
rent data is needed. Ideally, future studies should longitudinally
evaluate liver health in all children treated for cancer. Follow-up
should be long enough and complete with precise and uniform
outcome definitions, including transaminases and synthetic indi-
cators of liver function. The development of imaging modalities
which may lead to non-invasive characterisation of the liver also
hold promise for this population. While the cancer survivor has
many end organ risks after therapy, it remains to be investigated
whether the unique regenerative capacity of the liver obviates fol-
low-up for hepatic late adverse effects or whether certain host or
therapy exposures lead to threshold effects for late liver injury.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aricò 1994
Methods Cohort study
Participants N of patients original cohort: 102; N of patients described study group: 102; N of patients
study group of interest: 102; N of patients with liver function tests: 102
Tumour: ALL; Time period diagnosis/treatment: 1977-1992; Age at diagnosis: nm; Age at
follow-up: median 10.5 (2.5-21.1) yr; F/M%: 45/55; BMI: nm
N of patients hepatitis virus infection: 23/102 (22.5%) anti-HCV+ , HCV-RNA+ and 7/102
(6.8%) anti-HCV+, HCV-RNA−
N of patients acute liver disease: nm
Follow-up duration: median 2.8 (0.1-12.5) yr after end of treatment; Completion of follow-
up: 100%
Interventions N of patients chemotherapy: 102/102 (100%); Chemotherapy type: nm; Chemotherapy dose:
nm
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: 101/102 (99.0%)
Outcomes Method of detection of hepatic late adverse effects: ALT (frequency of testing nm)
Definition of hepatic late adverse effects: ALT > upper limit of normal (35 IU/mL)
N of patients hepatic late adverse effects at end of follow-up: 22/102 (21.6%) of whom 5/102
(4.9%) had mild-to-moderate increase, 16/102 (15.7%) moderate increase and 1/102 (1.0%)
severe increase (>3.5 times upper limit of normal (35 IU/mL))
Risk factors: Chronic HCV infection: 16/23 (69.6%) with chronic HCV infection elevated
ALT versus 6/79 (7.6%) without chronic HCV infection elevated ALT (P<0.001) (Univariate)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Low risk Described study group consisted of more than 90% of the original
cohort
Complete follow-up assessment Low risk Outcomewas assessed formore than90%of the study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated deter-
minant
Adjustment important confounders High risk Important prognostic factors or follow-up were not taken into account
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Aricò 1994 (Continued)
Well defined study group High risk Type of chemotherapy was not mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Well defined risk estimation Low risk Chi2 was calculated
Ballauff 1999
Methods Prospective cohort study
Participants N of patients original cohort: 50; N of patients described study group: 50; N of patients study
group of interest: 50; N of patients with liver function tests: 50
Tumour: various tumours; Time period diagnosis/treatment: 1980-1991; Age at diagnosis:
nm; Age at follow-up: median 12.3 (6.7-24.5) yr; F/M%: 36/64; BMI: nm
N of patients hepatitis virus infection: 14/50 (28.0%) anti-HCV+, HCV-RNA+, 2/50 (4.0%)
anti-HCV+ , HCV-RNA− and 2/50 (4.0%) HBsAntigen+
N of patients acute liver disease: 43/50 (86.0%) elevated AST/ALT during chemotherapy; 13/
50 (26.0%) elevated bilirubin and GGT during chemotherapy
Follow-up duration: median 3.6 (0.5-11.8) yr after end of treatment; Completion of follow-
up: 100%
Interventions N of patients chemotherapy: 50/50 (100%); Chemotherapy type: nm; Chemotherapy dose:
nm
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: 50/50 (100%)
Outcomes Method of detection of hepatic late adverse effects: ALT, AST, bilirubin, GGT (frequency of
testing nm)
Definition of hepatic late adverse effects: ALT > normal (24 U/L), AST > normal (22 U/L),
bilirubin >1.5 mg/dL (normal: 0.3 mg/dL), GGT >100 U/L (normal: 20 U/L)
N of patients hepatic late adverse effects at end of follow-up: 16/50 (32.0%)
Risk factors: Chronic HBV/HCV infection: 13/16 (81.3%) with abnormal liver function tests
chronic HBV/HCV infection versus 2/34 (5.9%) with normal liver function tests chronic
HBV/HCV infection (P=0.001) (Univariate)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Low risk Described study group consisted of more than 90% of the original
cohort
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Ballauff 1999 (Continued)
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the study group of
interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated de-
terminant
Adjustment important confounders High risk Important prognostic factors or follow-up were not taken into
account
Well defined study group High risk Type of chemotherapy was not mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome High risk Outcome definition was not objective and precise
Well defined risk estimation Low risk Chi2 was calculated
Bessho 1994
Methods Cohort study
Participants N of patients original cohort: nm; N of patients described study group: 25; N of patients study
group of interest: 25; N of patients with liver function tests: 25
Tumour: ALL; Time period diagnosis/treatment: nm; Age at diagnosis: median 4.4 (1.2-15.0) yr;
Age at follow-up: median 15.0 (6.8-22.0) yr; F/M%: 41/59; BMI: nm
N of patients hepatitis virus infection: 0/23 (0.0%) anti-HCV+ and 0/23 (0.0%) HBsAntigen+
N of patients acute liver disease: 24/25 (96.0%) elevated ALT during chemotherapy and 20/25
(80.0%) elevated ALT at end chemotherapy
Follow-up duration: median 4.2 (1.0-7.5) yr after end of treatment; Completion of follow-up:
100%
Interventions N of patients chemotherapy: 25/25 (100%); Chemotherapy type: prednisolone, vincristine,
daunorubicin, L-asparaginase, methotrexate and 6-mercaptopurine; Chemotherapy dose: Induc-
tion therapy consisted of daily prednisolone 60 mg/m2 for 4 weeks, 5 doses of weekly vincristine 1.
5 mg/m2, 5 doses of weekly daunorubicin 25 mg/m2 and 4 doses of weekly L-asparaginase 10,000
U/m2 or 8 doses of biweekly L-asparaginase 6000 U/m2. Prophylaxis of central nervous system
leukaemia consisted of 5 doses weekly methotrexate 12 mg/m2. Maintenance therapy consisted of
daily 6-mercaptopurine and weekly methotrexate. Initial doses of methotrexate and 6-mercaptop-
urine were 20 mg/m2 and 50 mg/m2, respectively. Mean methotrexate dose actually administered:
3.35 ± 1.27 g/m2. Mean 6-mercaptopurine dose actually administered: 59.65 ± 21.16 g/m2
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: 23/25 (92.0%)
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Bessho 1994 (Continued)
Outcomes Method of detection of hepatic late adverse effects: ALT, bilirubin, albumin, PTT (measured 3-12
monthly 1 yr after the end of treatment)
Definition of hepatic late adverse effects: ALT > upper limit of normal (33.3 IU/L); bilirubin,
albumin, PTT: nm
N of patients hepatic late adverse effects at end of follow-up: ALT: 2/25 (8.0%); bilirubin, albumin
and PTT: 0/25 (0.0%)
Risk factors: not evaluated
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted ofmore than90%of the original
cohort or if it was a random sample with respect to cancer treatment
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated determinant
Well defined study group Low risk Type of chemotherapy and number of patients with hepatitis virus infec-
tion were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Bresters 2008
Methods Retrospective cohort study
Participants N of patients original cohort: 290; N of patients described study group: 216; N of patients
study group of interest: 216; N of patients with liver function tests: 216
Tumour: ALL, AML,CML, JMML,MDS, lymphoma (n=129), benign haematological disease
(n=54), immunological disease (n=22), other inborn errors (n=11); Time period diagnosis/
treatment: 1980-2002; Age at diagnosis: nm (age at HSCT: median 7.6 (0.1-18.4) yr); Age at
follow-up: nm; F/M%: 40/60; BMI: nm
N of patients hepatitis virus infection: 3/139 (2.1%) anti-HCV+ and 0/183 (0.0%) HBsAnti-
gen+
N of patients acute liver disease: 14/216 (6.5%) VOD and 5/216 (2.3%) acute GVHD
Follow-up duration: 2 yr after HSCT, plus or minus 6 months; Completion of follow-up:
100%
Interventions N of patients chemotherapy: 211/216 (97.7%); Chemotherapy type: cyclophosphamide (n=
121), cyclophosphamide with busulphan (n=69), other unspecified (n=21); Chemotherapy
dose: nm
N of patients radiotherapy involving the liver: 132/216 (61.1%); Radiotherapy field: TBI/
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TAI; Radiotherapy dose: nm
N of patients hepatectomy: nm
N of patients BMT: 216/216 (100%)
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: ALT, AST (frequency of testing nm)
Definition of hepatic late adverse effects: ALT and/or AST > upper limit of normal (mean plus
2 standard deviations as determined in a normal Dutch population)
N of patients hepatic late adverse effects at end of follow-up: 53/216 (24.5%) of whom 17/216
(7.9%) had ALT/AST ≥2 times upper limit of normal. In 12/13 (92.3%) patients with ALT/
AST ≥2 times upper limit of normal persisting abnormal liver enzymes 3 years after HSCT
Risk factors: Older age at HSCT: median age 9.9 yr in patients with elevated ALT/AST versus
7.2 yr in patients with normal ALT/AST (P=0.027); diagnosis of benign haematological disease
(OR, 2.59; 95%CI, 1.32-5.05) (P=0.005); gender, donor type (matched sibling donor, other),
stem cell source (bonemarrow, autologous peripheral blood, cord blood), conditioning regimen
(cyclophosphamide with TBI/TAI, cyclophosphamide with busulphan, other) and early post-
transplant morbidity (viral reactivation after HSCT, VOD, acute GVHD) (ns) (Univariate)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group High risk Described study group consisted of less than 90% of the original
cohort and was no random sample of the original cohort with
respect to cancer treatment
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the study group of
interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated
determinant
Adjustment important confounders High risk Important prognostic factors or follow-up were not taken into
account
Well defined study group Low risk Type of chemotherapy, location of radiotherapy and number of
patients with hepatitis virus infection were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Well defined risk estimation Low risk Odds ratio, mean difference and Chi2 were calculated
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Chotsampancharoen 2009
Methods Prospective cohort study
Participants N of patients original cohort: 205a ; N of patients described study group: 133; N of patients
study group of interest: 133; N of patients with liver function tests: nm
Tumour: ALL, AML, CML; Time period diagnosis/treatment: 1990-2005; Age at diagnosis:
nm (age at HSCT: mean 9.1 ± 5.6 (0.6-21.4) yr); Age at follow-up: nm; F/M%: 46/54; BMI:
nm
N of patients hepatitis virus infection: nm
N of patients acute liver disease: nm
Follow-up duration: mean 5.6 ± 3.5 (1-15) yr after HSCT; Completion of follow-up: unclear
Interventions N of patients chemotherapy: nm; Chemotherapy type: nm; Chemotherapy dose: nm
N of patients radiotherapy involving the liver: 127/133 (95.5%); Radiotherapy field: TBI;
Radiotherapy dose: 8-14.4 Gya
N of patients hepatectomy: nm
N of patients BMT: 133/133 (100%)
N of patients blood transfusion: 133/133 (100%)
Outcomes Method of detection of hepatic late adverse effects: ALT, total bilirubin (frequency of testing
nm)
Definition of hepatic late adverse effects: nm
N of patients hepatic late adverse effects at end of follow-up: nm
Risk factors: High serum ferritin (iron overload): serum ferritin was positively correlated with
ALT (r=0.17) and total bilirubin (r=0.21) (P<0.001) (Univariate)
Notes a Reported in Leung 2007
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group High risk Described study group consisted of less than 90% of the original
cohort and was no random sample of the original cohort with
respect to cancer treatment
Complete follow-up assessment Unclear risk Unclear if outcome was assessed for more than 60% of the study
group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated de-
terminant
Adjustment important confounders High risk Important prognostic factors or follow-up were not taken into
account
Well defined study group High risk Number of patients with hepatitis virus infection was not men-
tioned
Well defined follow-up Low risk Length of follow-up was mentioned
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Chotsampancharoen 2009 (Continued)
Well defined outcome High risk Outcome definition was not objective and precise
Well defined risk estimation Low risk Chi2 was calculated
Frisk 1998
Methods Retrospective and prospective cohort study
Participants N of patients original cohort: 40; N of patients described study group: 40; N of patients study
group of interest: 40; N of patients with liver function tests: 40
Tumour: ALL, AML, NHL, HL (n=30), non-malignant disease (n=10); Time period diagnosis/
treatment: From 1985 onwards; Age at diagnosis: nm (age at BMT: median 7.6 (0.5-18.2) yra ;
Age at follow-up: nm; F/M%: 39/61a ; BMI: nm
N of patients hepatitis virus infection: 1/40 (2.5%) anti-HCV+, HCV-RNA+
N of patients acute liver disease: 52/64 (81.3%) elevated aminotransferases and/or bilirubin early
after BMTa ; 3/64 (4.7%) VODa ; 4/64 (6.3%) acute GVHDa
Follow-up duration: median 5.0 (1.0-10.0) yr after BMT; Completion of follow-up: 100%
Interventions N of patients chemotherapy: minimal 33/40 (82.5%); Chemotherapy type: prednisone, tenipo-
side, daunorubicin, vincristine, cyclophosphamide, busulphan, BCNU, etoposide, cytarabine, cy-
closporin and methotrexate; Chemotherapy dose: nm
N of patients radiotherapy involving the liver: 20/40 (50.0%); Radiotherapy field: TBI; Radio-
therapy dose: 7.5 Gy
N of patients hepatectomy: nm
N of patients BMT: 40/40 (100%)
N of patients blood transfusion: minimal 1/40 (2.5%)
Outcomes Method of detection of hepatic late adverse effects: ALT, AST, ALP, bilirubin, PTT (measured
annually 1 yr after BMT)
Definition of hepatic late adverse effects: nm
N of patients hepatic late adverse effects at end of follow-up: 6/40 (15.0%)
Risk factors: not evaluated
Notes a Data of 64 patients with BMT
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Low risk Described study group consisted of more than 90%
of the original cohort
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the
study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the
investigated determinant
29Hepatic late adverse effects after antineoplastic treatment for childhood cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Frisk 1998 (Continued)
Well defined study group Low risk Type of chemotherapy, location of radiotherapy and
number of patients with hepatitis virus infection
were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome High risk Outcome definition was not objective and precise
Guido 1991
Methods Cohort study
Participants N of patients original cohort: nm; N of patients described study group: 54 with liver biopsy within
3 months after end chemotherapy; N of patients study group of interest: 54; N of patients with
liver function tests: 19 with abnormal liver function 3 months after chemotherapy
Tumour: ALL; Time period diagnosis/treatment: 1979-1988; Age at diagnosis: mean 5.0, median
4.5 (1.5-11.0) yra ; Age at follow-up: nm; F/M%: 49/51a ; BMI: nm
N of patients hepatitis virus infection: 6/19 (31.6%) anti-HCV+, 4/19 (21.1%) HBsAntigen+ of
whom 1/19 (5.3%) anti-HDV+ co-infection
N of patients acute liver disease: 19/19 (100%) elevated ALT during chemotherapy; liver biopsy
3 months after end chemotherapy: 7/19 (36.8%) fibrosis, 8/19 (42.1%) acute hepatitis, 2/19 (10.
5%) chronic persistent hepatitis, 1/19 (5.3%) chronic lobular hepatitis, 1/19 (5.3%) chronic active
hepatitis and 0/19 (0.0%) cirrhosis
Follow-up duration: mean 3.2 (2-7) yr after end of treatmenta ; Completion of follow-up: 35.2%
Interventions N of patients chemotherapy: 19/19 (100%); Chemotherapy type: vincristine, prednisone, L-as-
paraginase, doxorubicin, daunorubicin, methotrexate, 6-mercaptopurine, cytosine arabinoside, 6-
thioguanine, cyclophosphamide, hydroxyurea, BCNU; Chemotherapy dose: nm
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: 19/19 (100%)
Outcomes Method of detection of hepatic late adverse effects: ALT (measured 3-6 monthly 1 yr after the end
of treatment)
Definition of hepatic late adverse effects: elevated ALT
N of patients hepatic late adverse effects at end of follow-up: 16/19 (84.2%)
Risk factors: not evaluated
Notes a Data of 72 patients with ALL with liver biopsy within 3 months after chemotherapy
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Representative study group Unclear risk Unclear if described study group consisted ofmore than90%of the original
cohort or if it was a random sample with respect to cancer treatment
Complete follow-up assessment High risk Outcome was assessed for less than 60% of the study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated determinant
Well defined study group Low risk Type of chemotherapy and number of patients with hepatitis virus infec-
tion were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome High risk Outcome definition was not objective and precise
Jagt 2009
Methods Retrospective cohort study
Participants N of patients original cohort: nm; N of patients described study group: 91; N of patients study
group of interest: 91; N of patients with liver function tests: 64
Tumour: Wilms’ tumour; Time period diagnosis/treatment: 1986-2006; Age at diagnosis: range
0.2-10.9 yra ; Age at follow-up: nm; F/M%: 40/60a ; BMI: nm
N of patients hepatitis virus infection: nm
N of patients acute liver disease: minimal 13/64 (20.3%) VOD
Follow-up duration: nm (≥5 yr after end of treatment); Completion of follow-up: 70.3%
Interventions N of patients chemotherapy: 64/64 (100%); Chemotherapy type: vincristine, actinomycin, epiru-
bicin and doxorubicin; Chemotherapy dose: weekly 1.5 mg/kg vincristine, 4 courses 15 µg/kg
actinomycin on 3 subsequent days, or 2 courses 15 µg/kg actinomycin on 3 subsequent days,
or 2 courses 45 µg/kg actinomycin once every 2 weeks, and 2 courses 50 mg/m2 epirubicin or
doxorubicin
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: ALT, AST, GGT, ALP (frequency of testing
nm)
Definition of hepatic late adverse effects: any value higher than age-dependent upper limit of
normal
N of patients hepatic late adverse effects at end of follow-up: 33/64 (51.6%)
Risk factors: not evaluated
Notes a Data of 91 patients in the described study group
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of more than 90% of the
original cohort or if it was a random sample with respect to cancer
treatment
Complete follow-up assessment Low risk Outcome was assessed for more than 60% of the study group of
interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated deter-
minant
Well defined study group High risk Number of patients with hepatitis virus infection was not mentioned
Well defined follow-up High risk Length of follow-up was not mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Locasciulli 1983
Methods Retrospective and prospective cohort study
Participants N of patients original cohort: nm; N of patients described study group: 70 with abnormal liver
function during chemotherapy; N of patients study group of interest: 70; N of patients with
liver function tests: 56
Tumour: ALL, ANLL; Time period diagnosis/treatment: 1972-1981; Age at diagnosis: mean
8 (4-19) yra ; Age at follow-up: nm; F/M%: 43/57b ; BMI: nm
N of patients hepatitis virus infection: 30/56 (53.6%) HBVmarkers (i.e. antigens or antibodies
for HBV)
N of patients acute liver disease: 56/56 (100%) elevated ALT/AST during chemotherapy; liver
biopsy in 38 patients at end chemotherapy: 5/38 (13.1%) chronic lobular hepatitis, 17/38 (44.
7%) chronic persistent hepatitis and 9/38 (23.6%) chronic active hepatitis
Follow-up duration: mean 2.0 (0.5-7.0) yr after end of treatment; Completion of follow-up:
80.0%
Interventions N of patients chemotherapy: 56/56 (100%); Chemotherapy type: vincristine, prednisone,
6-mercaptopurine, methotrexate, vinblastine, L-asparaginase, daunorubicin, cytosine arabi-
noside, doxorubicin, cyclophosphamide, 6-thioguanine; Chemotherapy dose: nm
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: 53/56 (94.6%)
Outcomes Method of detection of hepatic late adverse effects: ALT, AST (measured 3-6 monthly)
Definition of hepatic late adverse effects: ALT/AST >3 times upper limit of normal (60 IU/L)
for ≥6 months
N of patients hepatic late adverse effects at end of follow-up: ≥6 months: 22/56 (39.3%), <6
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months: 10/56 (17.9%)
Risk factors: Cleared or persistent chronic HBV infection: 17/22 (77.3%) with persistently
high transaminases HBVmarkers versus 3/24 (12.5%) with normal transaminases HBVmark-
ers (P<0.001); histological diagnosis of chronic hepatitis: 19/27 (70.4%) with histological di-
agnosis of chronic hepatitis persistently elevated transaminases versus 1/4 (25.0%) with mini-
mal changes persistently elevated transaminases (P<0.005) (Univariate)
Notes a Data of 103 patients with ALL/ANLL
b Data of 70 patients in the original cohort
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of
more than 90% of the original cohort or if it was
a random sample with respect to cancer treat-
ment
Complete follow-up assessment Low risk Outcomewas assessed formore than 60% of the
study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the
investigated determinant
Adjustment important confounders High risk Important prognostic factors or follow-up were
not taken into account
Well defined study group Low risk Type of chemotherapy and number of patients
with hepatitis virus infection were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Well defined risk estimation Low risk Chi2 was calculated
Locasciulli 1985
Methods Prospective cohort study
Participants N of patients original cohort: nm; N of patients described study group: 89 with abnormal liver
function during chemotherapy; N of patients study group of interest: 89; N of patients with liver
function tests: 48
Tumour: ALL, ANLL; Time period diagnosis/treatment: 1979; Age at diagnosis: mean 4.8 (0.3-
14.0) yra ; Age at follow-up: nm; F/M%: 46/54a ; BMI: nm
N of patients hepatitis virus infection: 23/48 (47.9%) HBsAntigen+
N of patients acute liver disease: 48/48 (100%) elevated ALT during chemotherapy
33Hepatic late adverse effects after antineoplastic treatment for childhood cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Locasciulli 1985 (Continued)
Follow-up duration: mean 2.8 (0.5-4.1) yr after end of treatment; Completion of follow-up: 53.
9%
Interventions N of patients chemotherapy: 48/48 (100%); Chemotherapy type: vincristine, prednisone, 6-mer-
captopurine, methotrexate, L-asparaginase, cytosine arabinoside, 6-thioguanine, doxorubicin, cy-
clophosphamide, BCNU, daunorubicin; Chemotherapy dose: nm
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: ALT (frequency of testing nm)
Definition of hepatic late adverse effects: ALT >3 times upper limit of normal (60 IU/L) for ≥6
months
N of patients hepatic late adverse effects at end of follow-up: 33/48 (68.8%)
Risk factors: not evaluated
Notes a Data of 164 patients with ALL/ANLL
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of more than 90% of the
original cohort or if it was a random sample with respect to cancer
treatment
Complete follow-up assessment High risk Outcome was assessed for less than 60% of the study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated determi-
nant
Well defined study group Low risk Type of chemotherapy and number of patients with hepatitis virus
infection were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Locasciulli 1991a
Methods Cohort study
Participants N of patients original cohort: 174; N of patients described study group: 50 with abnormal
liver function during chemotherapy; N of patients study group of interest: 50; N of patients
with liver function tests: 50
Tumour: ALL (n=40), AML (n=8), CML (n=1), RAEB (n=1); Time period diagnosis/treat-
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ment: 1969-1989; Age at diagnosis: mean 5.8 (0.8-16.6) yr; Age at follow-up: nm; F/M%:
40/60; BMI: nm
N of patients hepatitis virus infection: 12/50 (24.0%) anti-HCV+ , RIBA+ and 14/50 (28.0%)
HBsAntigen+
N of patients acute liver disease: 50/50 (100%) elevatedALTduring chemotherapy; liver biopsy
in 37 patients at end chemotherapy: 7/37 (18.9%) nonspecific reactive hepatitis, 13/37 (35.
1%) chronic lobular hepatitis, 12/37 (32.4%) chronic persistent hepatitis and 10/37 (27.0%)
chronic active hepatitis
Follow-up duration:mean 6.2 ± 3.4 (1.0-12.6) yr after end of treatment; Completion of follow-
up: 100%
Interventions N of patients chemotherapy: 50/50 (100%); Chemotherapy type: nm; Chemotherapy dose:
nm
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: 13/50 (26.0%)
N of patients blood transfusion: 48/50 (96.0%)
Outcomes Method of detection of hepatic late adverse effects: ALT (measured 3-6 monthly)
Definition of hepatic late adverse effects: ALT > upper limit of normal (40 IU/L)
N of patients hepatic late adverse effects at end of follow-up: 20/50 (40.0%)
Risk factors: Chronic HCV infection: 11/12 (91.7%) with chronic HCV infection persistently
elevated ALT versus 8/27 (29.6%) without chronic HCV infection persistently elevated ALT
(P=0.0012) (Univariate)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group High risk Described study group consisted of less than90%of the original cohort
andwas no random sample of the original cohort with respect to cancer
treatment
Complete follow-up assessment Low risk Outcomewas assessed formore than90%of the study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated deter-
minant
Adjustment important confounders High risk Important prognostic factors or follow-up were not taken into account
Well defined study group High risk Type of chemotherapy was not mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
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Well defined risk estimation Low risk Mean difference was calculated
Locasciulli 1997a
Methods Prospective cohort study
Participants N of patients original cohort: 125; N of patients described study group: 114; N of patients
study group of interest: 114; N of patients with liver function tests: 114
Tumour: ALL, AML; Time period diagnosis/treatment: 1968-1982; Age at diagnosis: mean 4
± 2.6 yr; Age at follow-up: nm; F/M%: 48/52; BMI: nm
N of patients hepatitis virus infection: 28/114 (24.6%) anti-HCV+, HCV-RNA+ and 19/114
(16.7%) anti-HCV+ , HCV-RNA−
N of patients acute liver disease: 54/111 (48.7%) elevated ALT at end chemotherapy; liver
biopsy in 36 patients at end chemotherapy: 5/36 (13.9%) nonspecific reactive hepatitis, 9/36
(25.0%) chronic lobular hepatitis, 15/36 (41.7%) chronic persistent hepatitis and 7/36 (19.
4%) chronic active hepatitis
Follow-up duration: mean 17 ± 3.2 (13-27) yr after end of treatment; Completion of follow-
up: 100%
Interventions N of patients chemotherapy: 114/114 (100%); Chemotherapy type: nm; Chemotherapy dose:
nm
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: ALT (measured yearly), liver biopsy (n=2
at follow-up of 5 and 7 yr, respectively)
Definition of hepatic late adverse effects: ALT > upper limit of normal (42 IU/L)
N of patients hepatic late adverse effects at end of follow-up: ALT: 33/114 (28.9%) of whom 4/
114 (3.5%) had constantly abnormal values and 29/114 (25.4%) fluctuations from normal to
abnormal values; liver biopsy: 1/2 (50.0%) chronic persistent hepatitis, 1/2 (50.0%) chronic
lobular hepatitis
Risk factors: Chronic HCV infection: 22/28 (78.6%) with chronic HCV infection elevated
ALT versus 11/86 (12.8%) without chronic HCV infection elevated ALT (P=0.008) (Univari-
ate)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Low risk Described study group consisted of more than 90% of the original
cohort
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Locasciulli 1997a (Continued)
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the study group of
interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated de-
terminant
Adjustment important confounders High risk Important prognostic factors or follow-up were not taken into
account
Well defined study group High risk Type of chemotherapy was not mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Well defined risk estimation Low risk Chi2 was calculated
Locasciulli 1997b
Methods Prospective cohort study
Participants N of patients original cohort: 53; N of patients described study group: 53; N of patients study
group of interest: 53; N of patients with liver function tests: 53
Tumour: ALL, AML, CML, JCML, Histiocytosis X, SAA, RAEB; Time period diagnosis/treat-
ment: 1985-1995; Age at diagnosis: nm (age at BMT: mean 9.4 (0.9-18.0) yra ; Age at follow-up:
nm; F/M%: 34/66a ; BMI: nm
N of patients hepatitis virus infection: minimal 9/53 (17.0%) ant-HCV+, HCV-RNA+, minimal
5/53 (9.4%) anti-HCV+, HCV-RNA− and 2/53 (3.8%) HBsAntigen+
N of patients acute liver disease: 82/111 (73.9%) elevated ALT after BMTa ; 4/111 (3.6%) VOD
leading to multi-organ failurea
Follow-up duration: range 1.3-10.9 yr after BMT; Completion of follow-up: 100%
Interventions N of patients chemotherapy: 53/53 (100%); Chemotherapy type: cyclophosphamide, cytarabine,
vincristine, etoposide, busulphan, melphalan, cyclosporine andmethotrexate; Chemotherapy dose:
120 mg/kg cyclophosphamide was given as 2 daily doses of 60 mg/kg, alone, or in combination
with high-dose cytarabine 3 mg/m2 for 2 days, high-dose vincristine 4 mg/m2 in 4 days, etoposide
60mg/kg in 1 day, busulphan 16 mg/kg as 4 daily doses and melphalan 140 mg/m2. Children
with SAA were conditioned with 200 mg/kg cyclophosphamide given in divided doses on 4 days.
Cyclosporine and methotrexate dose: nm
N of patients radiotherapy involving the liver: nm (76/111 (68.5%))a ; Radiotherapy field: TBI;
Radiotherapy dose: 12 Gy
N of patients hepatectomy: nm
N of patients BMT: 53/53 (100%)
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: ALT (measured 3 monthly)
Definition of hepatic late adverse effects: ALT > upper limit of normal (42 IU/L) for ≥6 months
N of patients hepatic late adverse effects at end of follow-up: 28/53 (52.8%)
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Locasciulli 1997b (Continued)
Risk factors: not evaluated
Notes a Data of 111 patients with BMT
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Low risk Described study group consisted of more than 90% of the original
cohort
Complete follow-up assessment Low risk Outcome was assessed formore than 90% of the study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated determi-
nant
Well defined study group Low risk Type of chemotherapy, locationof radiotherapy andnumber of patients
with hepatitis virus infection were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Matsuzaki 2001
Methods Prospective cohort study
Participants N of patients original cohort: nm; N of patients described study group: 132; N of patients study
group of interest: 132; N of patients with liver function tests: 105
Tumour: ALL; Time period diagnosis/treatment: 1984-1990; Age at diagnosis: nm; Age at follow-
up: nm; F/M%: 42/58a ; BMI: nm (one patient with obesity)
N of patients hepatitis virus infection: 9/105 (8.6%) HCV infection (not specified)
N of patients acute liver disease: nm
Follow-up duration: nm; Completion of follow-up: 79.5%
Interventions N of patients chemotherapy: 105/105 (100%); Chemotherapy type: vincristine, prednisolone, L-
asparaginase, daunorubicin, cytosine arabinoside, methotrexate, 6-mercaptopurine, enocitabine,
doxorubicin, dexamethasone and cyclophosphamidea ; Chemotherapy dose: induction consisted
of 4 times 2 mg/m2 vincristine, 4 weeks 60 mg/m2 prednisolone, 7 times 10,000 U/m2 L-asparag-
inase, 2 times 25 mg/m2 daunorubicin and 4 times 500 mg/m2 cytosine arabinoside. Consolida-
tion consisted of 300 + 400 mg/m2 or 2 times 500 mg/m2 methotrexate, 14 days 120 mg/m2 6-
mercaptopurine and 8 times 150 mg/m2 enocitabine. Reinduction consisted of 4 times 2 mg/m2
vincristine, 2 to 4 weeks 8 mg/m2 dexamethasone, 4 times 1 g/m2 high-dose cytosine arabinoside
and 1 time 10,000 U/m2 L-asparaginase. Maintenance consisted of 4 days 120 mg/m2 6-mer-
captopurine, 600 mg/m2 intravenous cyclophosphamide, 4 days 70 mg/m2 cyclophosphamide by
mouth, 45 mg/m2 daunorubicin, 200 mg/m2 cytosine arabinoside, 4 days 10 mg/m2 methotrexate
and 2 mg/m2 vincristinea
N of patients radiotherapy involving the liver: 0 (0.0%); Radiotherapy field: not applicable; Ra-
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diotherapy dose: not applicable
N of patients hepatectomy: nm
N of patients BMT: 0 (0.0%)
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: transaminase (frequency of testing nm)
Definition of hepatic late adverse effects: transaminase <100 IU/L
N of patients hepatic late adverse effects at end of follow-up: 19/105 (18.1%)
Risk factors: not evaluated
Notes a Data of 187 patients with ALL
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of more than 90% of the
original cohort or if it was a random sample with respect to cancer
treatment
Complete follow-up assessment Low risk Outcome was assessed formore than 60% of the study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated determi-
nant
Well defined study group Low risk Type of chemotherapy and number of patients with hepatitis virus
infection were mentioned
Well defined follow-up High risk Length of follow-up was not mentioned
Well defined outcome High risk Outcome definition was not objective and precise
Ratner 1986
Methods Retrospective cohort study
Participants N of patients original cohort: nm; N of patients described study group: 39; N of patients study
group of interest: 39; N of patients with liver function tests: 39
Tumour: ALL; Time period diagnosis/treatment: 1971-1980; Age at diagnosis: nm; Age at follow-
up: nm; F/M%: nm; BMI: nm
N of patients hepatitis virus infection: 5/39 (12.8%) HBsAntigen+ of whom 3/39 (7.7%) anti-
HDV+ co-infection
N of patients acute liver disease: 50/79 (63.3%) elevated ALT during maintenance therapya
Follow-up duration: range 1.0-8.3 yr after end of treatment; Completion of follow-up: 100%
Interventions N of patients chemotherapy: 39/39 (100%); Chemotherapy type: vincristine, 6-mercaptopurine,
methotrexate, asparaginase, cyclophosphamide, daunorubicin, hydroxyurea and prednisone; Che-
motherapy dose: nm
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N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: ALT (measured 6 monthly), liver biopsy (n=3)
Definition of hepatic late adverse effects: ALT >2 times upper limit of normal (90 U/L)
N of patients hepatic late adverse effects at end of follow-up: ALT: 9/39 (23.1%); liver biopsy: 3/
3 (100%) cirrhosis
Risk factors: not evaluated
Notes a Data of 79 patients with ALL
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of more than 90% of the
original cohort or if it was a random sample with respect to cancer
treatment
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the study group of
interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated deter-
minant
Well defined study group Low risk Type of chemotherapy and number of patients with hepatitis virus
infection were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Rossetti 1991
Methods Cohort study
Participants N of patients original cohort: nm; N of patients described study group: 145; N of patients
study group of interest: 145; N of patients with liver function tests: 96
Tumour: ALL; Time period diagnosis/treatment: 1967-1983; Age at diagnosis: nm; Age at
follow-up: range 6-26 yr; F/M%: 49/51; BMI: nm
N of patients hepatitis virus infection: 60/96 (62.5%) HBsAntigen+ of whom 30/96 (31.3%)
anti-HDV+ co-infection
N of patients acute liver disease: 40/96 (41.7%) elevated ALT during chemotherapy; liver
biopsy in 72 patients within 3 months after chemotherapy: 27/72 (37.5%) chronic active
hepatitis or cirrhosis and 10/72 (13.9%) chronic persistent/lobular hepatitis
Follow-up duration: range 4-20 yr from diagnosis, ≥2.0 yr after end of treatment; Completion
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of follow-up: 66.2%
Interventions N of patients chemotherapy: 96/96 (100%); Chemotherapy type: vincristine, L-asparaginase,
doxorubicin, daunorubicin,methotrexate (high-dose) 6-mercaptopurine, cytosine arabinoside,
6-thioguanine, cyclophosphamide, hydroxyurea and BCNU; Chemotherapy dose: nm
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: ALT (measured 3 monthly), albumin
(frequency of testing nm)
Definition of hepatic late adverse effects: ALT >2 times upper limit of normal (100 IU/L);
Albumin nm
N of patients hepatic late adverse effects at end of follow-up: ALT:43/96 (44.8%); Albumin:
0/96 (0.0%)
Risk factors: Chronic HBV-HDV co-infection and chronic HBV infection: 27/30 (90.0%)
with chronic HBV-HDV co-infection elevated ALT versus 10/26 (38.5%) with chronic HBV
infection elevated ALT versus 6/40 (15.0%) without chronic HBV infection elevated ALT
(P<0.02) (Univariate)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of more than 90% of the
original cohort or if it was a random sample with respect to cancer
treatment
Complete follow-up assessment Low risk Outcomewas assessed formore than60%of the study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated deter-
minant
Adjustment important confounders High risk Important prognostic factors or follow-up were not taken into account
Well defined study group Low risk Type of chemotherapy and number of patients with hepatitis virus
infection were mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
Well defined risk estimation Low risk Chi2 was calculated
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Methods Retrospective cohort study
Participants N of patients original cohort: 26; N of patients described study group: 26; N of patients study
group of interest: 26; N of patients with liver function tests: 26
Tumour: Hepatoblastoma; Time period diagnosis/treatment: 1981-1993; Age at diagnosis: median
1.3 (0.0 - 12.0)a ; Age at follow-up: nm; F/M%: 39/61a ; BMI: nm
N of patients hepatitis virus infection: nm
N of patients acute liver disease: nm
Follow-up duration: median 5.3 (0.1-12.2) yr; Completion of follow-up: 100%
Interventions N of patients chemotherapy: 24/26 (92.3%); Chemotherapy type: cisplatin, doxorubicin, carbo-
platin and etoposide; Chemotherapy dose: 3-weekly cisplatin (80-100 mg/m2) and doxorubicin
(50-60 mg/m2)
N of patients radiotherapy involving the liver: 2/26 (7.7%); Radiotherapy field: nm; Radiotherapy
dose: nm
N of patients hepatectomy: 26/26 (100%)
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: Biochemical liver function tests (frequency of
testing nm)
Definition of hepatic late adverse effects: nm
N of patients hepatic late adverse effects at end of follow-up: 0/26 (0.0%)
Risk factors: not evaluated
Notes a Data of 41 patients with hepatoblastoma
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Low risk Described study group consisted of more than 90% of the original
cohort
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the study group of
interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated deter-
minant
Well defined study group High risk Number of patients with hepatitis virus infection was not mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome High risk Outcome definition was not objective and precise
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Tefft 1970
Methods Retrospective cohort study
Participants N of patients original cohort: nm; N of patients described study group: 99; N of patients study
group of interest: 99; N of patients with liver function tests: 88
Tumour: Wilms’ tumour, neuroblastoma, hepatoma; Time period diagnosis/treatment: nm;
Age at diagnosis: 14% <1 yr, 56% 1-4 yr, 30% >5 yra ; Age at follow-up: nm; F/M%: 55/45a ;
BMI: nm
N of patients hepatitis virus infection: nm
N of patients acute liver disease: 31/51 (60.8%) abnormal liver function within 6 months
following radiotherapy
Follow-up duration: mean 3.9 (0.5-13.3) yr after end of treatment; Completion of follow-up:
88.9%
Interventions N of patients chemotherapy: 88/88 (100%); Chemotherapy type: vincristine, actinomycin D
and 5-fluorouracil; Chemotherapy dose: nm
N of patients radiotherapy involving the liver: 88/88 (100%); Radiotherapy field: right lobe
(n=36), left lobe (n=35), entire liver (n=13), remaining liver after resection (n=4); Radiotherapy
dose: <25 Gy (n=21), 25-35 Gy (n=47), >35 Gy (n=20)
N of patients hepatectomy: 4/88 (4.5%)
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: AST and other unspecified liver function
tests (frequency of testing nm)
Definition of hepatic late adverse effects: Abnormal liver function tests
N of patients hepatic late adverse effects at end of follow-up: 51/88 (58.0%)
Risk factors: site of radiotherapy: 25/36 (96.4%) with right lobe irradiation abnormal liver
function tests versus 16/35 (45.7%) with left lobe irradiation abnormal liver function tests
versus 6/13 (46.2%) with whole liver irradiation abnormal liver function tests versus 4/4
(100%) with remaining liver irradiation abnormal liver function tests (ns); radiotherapy dose:
11/21 (52.4%) with <25 Gy abnormal liver function tests versus 27/47 (57.4%) with 25-35
Gy abnormal liver function tests versus 12/20 (60.0%) with >35 Gy abnormal liver function
tests (ns) (Univariate)
Notes a Data of 115 patients
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of more than 90% of
the original cohort or if it was a random sample with respect to
cancer treatment
Complete follow-up assessment Low risk Outcome was assessed for more than 60% of the study group of
interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the investigated
determinant
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Adjustment important confounders High risk Important prognostic factors or follow-up were not taken into
account
Well defined study group High risk Number of patients with hepatitis virus infection was not men-
tioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome High risk Outcome definition was not objective and precise
Well defined risk estimation Low risk Chi2 was calculated
Vora 2006
Methods Prospective cohort study (originally developed as a RCT; a selected group of patients was followed
up for hepatic late adverse effects)
Participants N of patients original cohort: nm; N of patients described study group: 43 with splenomegaly
during chemotherapy; N of patients study group of interest: 43; N of patients with liver function
tests: 43
Tumour: lymphoblastic leukaemia; Time period diagnosis/treatment: 1997-2002; Age at diagnosis:
1.0-18.0 yr; Age at follow-up: nm; F/M%: nm; BMI: nm
N of patients hepatitis virus infection: nm
N of patients acute liver disease: 0/43 (0.0%) abnormal liver function tests <1 yr after end chemo-
therapy
Follow-up duration: mean 3.3 (0.0-5.4) yr after end of treatment; Completion of follow-up: 100%
Interventions N of patients chemotherapy: 43/43 (100%); Chemotherapy type: 6-thioguanine, 6-mercaptop-
urine, vincristine, methotrexate, L-asparaginase, prednisolone, dexamethasone (other chemother-
apeutic regimens not mentioned); Chemotherapy dose: 40 mg/m2/day 6-thioguanine, 75 mg/m
2/day 6-mercaptopurine (dose other chemotherapeutic regimens not mentioned)
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: aminotransferases, liver biopsy (n=10) (fre-
quency of testing nm)
Definition of hepatic late adverse effects: elevated aminotransferases
N of patients hepatic late adverse effects at end of follow-up: aminotransferases: 6/43 (14.0%);
liver biopsy: 10/10 (100%) portal fibrosis or nodular regenerative hyperplasia
Risk factors: not evaluated
Notes
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of
more than 90% of the original cohort or if it was
a random sample with respect to cancer treat-
ment
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the
study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the
investigated determinant
Well defined study group High risk Number of patients with hepatitis virus infec-
tion was not mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome High risk Outcome definition was not objective and pre-
cise
Weber 1987
Methods Prospective cohort study (originally developed as a RCT; a selected group of patients was followed
up for hepatic late adverse effects)
Participants N of patients original cohort: nm; N of patients described study group: 19; N of patients study
group of interest: 19; N of patients with liver function tests: 19
Tumour: ALL; Time period diagnosis/treatment: 1979-1981; Age at diagnosis: range 0.7-17.0 yr
a ; Age at follow-up: nm; F/M%: 47/53a ; BMI: nm
N of patients hepatitis virus infection: nm
N of patients acute liver disease: 19/19 (100%) elevatedALT after 6 courses of high-dosemethotrex-
ate
Follow-up duration: range 1.0-4.0 yr after end of treatment; Completion of follow-up: 100%
Interventions N of patients chemotherapy: 19/19 (100%); Chemotherapy type: vincristine, L-asparaginase,
daunomycin, methotrexate, prednisone, leucovorin, 6-mercaptopurine and cyclophosphamide;
Chemotherapy dose: A priming dose of methotrexate, 6000mg/m2 was administered over 1 hour
followed immediately by constant infusion of methotrexate, 1200 mg/m2/hour for 23 hours. The
total dose of methotrexate per course was 33,600 mg/m2 over 24 hours. Twelve hours after com-
pletion of the methotrexate infusion, 200 mg/m2 leucovorin was administered over 1 hour. Three
hours later, leucovorin was started at doses of 12 mg/m2 every 3 hours for 5 doses, then every 6
hours until the serum methotrexate level fell below 1x10−7M. Six 23-week cycles of prednisone,
vincristine, 6-mercaptopurine, L-asparaginase, cyclophosphamide, daunomycin, and twice weekly
methotrexate (7.5 mg/m2 during weeks 3 to 6, 10 to 13, and 17 to 20) were administered. Also
high-dose 6-mercaptopurine (500 mg/m2/day) on days 1 to 5 of each maintenance cycle was re-
ceived
N of patients radiotherapy involving the liver: nm; Radiotherapy field: nm; Radiotherapy dose:
45Hepatic late adverse effects after antineoplastic treatment for childhood cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Weber 1987 (Continued)
nm
N of patients hepatectomy: nm
N of patients BMT: nm
N of patients blood transfusion: nm
Outcomes Method of detection of hepatic late adverse effects: ALT, bilirubin, ALP (frequency of testing nm)
Definition of hepatic late adverse effects: > upper limits of normal: ALT 40 IU/L, total bilirubin
0.8 mg/dL, direct bilirubin 0.3 mg/dL, ALP 180 IU/L (1 yr of age until adolescence), 260 IU/L
(adolescent females), 350 IU/L (adolescent males)
N of patients hepatic late adverse effects at end of follow-up: 0/19 (0.0%)
Risk factors: not evaluated
Notes a Data of 36 patients with ALL
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Representative study group Unclear risk Unclear if described study group consisted of
more than 90% of the original cohort or if it was
a random sample with respect to cancer treat-
ment
Complete follow-up assessment Low risk Outcome was assessed for more than 90% of the
study group of interest
Blinded outcome assessor Unclear risk Unclear if outcome assessors were blinded to the
investigated determinant
Well defined study group High risk Number of patients with hepatitis virus infec-
tion was not mentioned
Well defined follow-up Low risk Length of follow-up was mentioned
Well defined outcome Low risk Outcome definition was objective and precise
ALL, acute lymphoblastic leukaemia; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AML, acute myeloid leukaemia; ANLL,
acute non-lymphoblastic leukaemia; AST, aspartate aminotransferase; BMI, body mass index; BMT, bone marrow transplantation;
CML, chronic myeloid leukaemia; GGT, gamma-glutamyl transferase; GVHD, graft-versus-host disease; HBV, hepatitis B virus;
HCV, hepatitis C virus; HDV, hepatitis D virus; HL, Hodgkin lymphoma; HSCT, haematopoietic stem cell transplantation; JCML,
juvenile chronic myeloid leukaemia; JMML, juvenile myelomonocytic leukaemia; MDS, myelodysplastic syndrome; NHL, non-
Hodgkin lymphoma; nm, not mentioned; ns, not significant; PTT, prothrombin time; RAEB, refractory anaemia with blast excess;
RCT, randomised controlled trial; RIBA, recombinant immunoblotting assay; SAA, severe aplastic anaemia; TAI, thoraco-abdominal
irradiation; TBI, total body irradiation; uc, unclear; VOD, veno-occlusive disease.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adson 1981 Less than 50% aged 18 years or younger
Al-Attar 1986 Not reporting on hepatic late adverse effects
Amylon 1997 Follow-up duration unclear
Atay 2005 Not reporting on hepatic late adverse effects
Avet Loiseau 1991 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Bacigalupo 1991 Not reporting on hepatic late adverse effects
Balcerska 2000 Follow-up duration unclear
Bauditz 2007 Case series
Benesch 2001 Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus
infection
Berjian 1980 No childhood cancer survivors: adult patients >18 years
Berman 1980 Less than 50% aged 18 years or younger
Bernstein 1993 Not reporting on hepatic late adverse effects
Blum 2002 Not reporting on hepatic late adverse effects
Broxson 2005 Case series
Brunet 2001 Less than 50% aged 18 years or younger
Carter 1997 Cancer treatment unclear
Cassady 1979 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Cavo 1998 No childhood cancer survivors: adult patients >18 years
Cesaro 1997 Liver function testing in hepatitis virus positive patients
Chao 1993 Less than 50% aged 18 years or younger
Cheng 2005 No childhood cancer survivors: adult patients >18 years
Cheuk 2008 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
47Hepatic late adverse effects after antineoplastic treatment for childhood cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Chou 1996 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Christosova 2005 Case series
Claviez 1996 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Colsky 1955 Case series
Condren 2005 Impossible to differentiate between patients with and without potentially high-risk treatment for hepatic
late adverse effects
Damon 2006 No childhood cancer survivors: adult patients >18 years
Deeg 1986 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Dibenedetto 1994 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Dunkel 1998 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Dupuis-Girod 1996 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Evans 1980 Not reporting on hepatic late adverse effects
Evans 1982 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Evans 1990 Less than 50% aged 18 years or younger
Evans 1993 Less than 50% aged 18 years or younger
Exelby 1975 Follow-up duration unclear
Fabbri 1994 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Farthing 1982 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Fink 1993 Impossible to differentiate between patients with and without potentially high-risk treatment for hepatic
late adverse effects
Forbes 1995 Less than 50% aged 18 years or younger
Frickhofen 1994 Less than 50% aged 18 years or younger
Gandola 2009 Not reporting on hepatic late adverse effects
Ganjoo 2006 No childhood cancer survivors: adult patients >18 years
Glick 2000 Less than 10 childhood cancer survivors
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Gluckman 1979 Unclear if one of our defined outcome measures was tested
Gonzalez-Crussi 1982 Not reporting on hepatic late adverse effects
Greenfield 2006 Not reporting on hepatic late adverse effects
Grill 1996 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Grosfeld 1976 Case series
Gutjahr 1980 Cancer treatment unclear
Haddy 1998 Liver function testing in hepatitis virus positive patients
Hadley 2002 Not reporting on hepatic late adverse effects
Halonen 2003 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Hanks 1980 Not reporting on hepatic late adverse effects
Harrison 1996 Less than 50% aged 18 years or younger
Hatanaka 1994 No childhood cancer survivors: adult patients >18 years
Haupt 2004 Unclear if one of our defined outcome measures was tested
Hedrick 2004 Not reporting on hepatic late adverse effects
Hegewald 1982 Not reporting on hepatic late adverse effects according to our defined outcome measures; Unclear if case
series or cohort study
Henderson 2008 Case report
Hjern 2007 Not reporting on hepatic late adverse effects
Ho 2004 No childhood cancer survivors: adult patients
Hollard 1980 Less than 50% aged 18 years or younger
Holschneider 1977 Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus
infection
Horowitz 1993 Not reporting on hepatic late adverse effects
Hutter 1960 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Ingold 1965 Case series
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Isaacs 2008 Not reporting on hepatic late adverse effects
Ivantes 2004 No childhood cancer survivors: adult patients
Jaffe 1975 Review
Jagannathan 2004 No childhood cancer survivors: adult patients >18 years
Jirtle 1990 Review
Kamani 1996 Unclear if one of our defined outcome measures was tested
Kamble 2006 Review
Kaste 1999 Not reporting on hepatic late adverse effects
Kazanowska 2004 Not reporting on hepatic late adverse effects
Khouri 2002 No childhood cancer survivors: adult patients >18 years
Kim 2000 No childhood cancer survivors: adult patients
Kotz 1982 Case series
Kremens 2002 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Kudo 1996 No childhood cancer survivors
Lackner 2000 Impossible to differentiate between patients with and without potentially high-risk treatment for hepatic
late adverse effects
Lackner 2007 Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus
infection
Ladenstein 1997 Not reporting on hepatic late adverse effects
Leonardi 2003 Cancer treatment unclear
Leung 2000 Liver function testing in hepatitis virus positive patients
Levitt 2004 Not reporting on hepatic late adverse effects according to our defined outcome measures
Ljungman 1995 Less than 50% aged 18 years or younger
Locasciulli 1989 Less than 50% aged 18 years or younger
Locasciulli 1990a Age of the patients unclear
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Locasciulli 1990b Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Locasciulli 1991b Less than 50% aged 18 years or younger
Locasciulli 1993 Liver function testing in hepatitis virus positive patients
Locasciulli 1995 Review
Maggiore 1982 Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus
infection
Maguire 2002 Not reporting on hepatic late adverse effects
Martinez 1997 No childhood cancer survivors: adult patients >18 years
Masera 1981 Liver function testing in hepatitis virus positive patients
McBride 1976 Less than 50% aged 18 years or younger
McIntosh 1977 Less than 10 childhood cancer survivors
McKay 1996 Less than 50% aged 18 years or younger
Meadows 1992 Unclear if one of our defined outcome measures was tested
Mitrou 1990 Not reporting on hepatic late adverse effects
Moore 1995 Not reporting on hepatic late adverse effects
Morrow 1982 Not reporting on hepatic late adverse effects
Murthy 1978 Not reporting on hepatic late adverse effects
Myers 1995 Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus
infection; Information on liver function reported for only 1 patient
Nagasue 1979 No childhood cancer survivors: adult patients >18 years
Nagatoshi 1997 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Neilson 1996 Age of the patients and cancer treatment unclear
O’Hara 1968 Not reporting on hepatic late adverse effects
Oeffinger 2006 Not reporting on hepatic late adverse effects
Osborne 1980 No childhood cancer survivors: adult patients >18 years
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Pantoja 1975 No childhood cancer survivors: adult patients >18 years
Pao 1989 Not reporting on hepatic late adverse effects
Park 2002 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Poussin-Rosillo 1976 Less than 50% aged 18 years or younger
Pratt 1977 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Pritchard 2005 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Pui 1992 Not reporting on hepatic late adverse effects
Punyko 2005 Not reporting on hepatic late adverse effects
Puri 2006 Not reporting on hepatic late adverse effects
Ravikumara 2006 Less than 50% off treatment for 1 year or more
Reaman 1985 Not reporting on hepatic late adverse effects
Rodriguez-Inigo 1997 No childhood cancer survivors: adult patients
Rossetti 1992 Number of patients with liver function testing unclear; Liver biopsy during first year after chemotherapy
(<1 year off treatment)
Samuelsson 1999 Not reporting on hepatic late adverse effects
Sawamura 1998 Not reporting on hepatic late adverse effects
Schaison 1980 Number of patients with liver function testing unclear
Sekine 1998 Number of patients with liver function testing unclear
Sevinir 2003 Liver function testing in hepatitis virus positive patients
Shah 2004 Not reporting on hepatic late adverse effects
Silverman 1997 Not reporting on hepatic late adverse effects
Skidmore 1997 No childhood cancer survivors: adult patients
Socié 1999 Less than 50% aged 18 years or younger
Socié 2001 Not reporting on hepatic late adverse effects
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Spunberg 1981 Not reporting on hepatic late adverse effects
Strasser 1999a Less than 50% aged 18 years or younger
Strasser 1999b Less than 50% aged 18 years or younger
Straus 1991 Not reporting on hepatic late adverse effects
Tada 1997 Liver function testing in hepatitis virus positive patients
Taylor 1997 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Tefft 1977 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Thomas 1988 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Tomás 2000 Less than 50% aged 18 years or younger
Tura 1998 No childhood cancer survivors: adult patients
Uchino 1978 Not reporting on hepatic late adverse effects
Uzel 2001 Not reporting on hepatic late adverse effects
Vaidya 2000 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
van den Ouweland 1983 Less than 50% aged 18 years or younger
Veneri 2003 No childhood cancer survivors: adult patients
Vergani 1982 Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus
infection; Liver biopsy at cessation of chemotherapy (<1 year off treatment)
von Schweinitz 1994 Not reporting on hepatic late adverse effects
Wasserheit 1995 Less than 50% aged 18 years or younger
Weirich 2004 Unclear if one of our defined outcome measures was tested
Wexler 1996 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Willers 2001 Liver function testing in hepatitis virus positive patients
Wolff 2006 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Woolfrey 1998 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
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(Continued)
Yamada-Osaki 1999 Liver function testing in hepatitis virus positive patients
Yang 2005 Not reporting on hepatic late adverse effects
Yang 2006 Not reporting on hepatic late adverse effects
Zimmermann 2002 Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Zittoun 1985 Less than 50% aged 18 years or younger
Characteristics of studies awaiting assessment [ordered by study ID]
Kovacs 2007
Methods Cohort study.
Participants 138 children (78 boys, 60 girls) aged 1-18 years (mean 7.7) with acute leukaemia and non-Hodgkin lymphoma
Interventions Patients were treated with chemotherapy. Specific details on cancer treatment are not reported
Outcomes 12.1% had elevated ALT and 3.0% elevated GGT at a follow-up of 1-4 years after the end of treatment. 8.2% had
elevated ALT and 0.0% elevated GGT at a follow-up >5 years after the end of treatment
Notes This study has not been published in full text (as of February 2010), but has been presented at the SIOP conference
2007 (abstract PL.004). From currently available data it is unclear if this study is eligible for inclusion in this review
Kristinsson 2002
Methods Cohort study
Participants 20 childhood cancer survivors treated for leukaemia. Age at diagnosis ranged from 0.4 to 13.8 years, mean age at
follow-up was 16.7 years and mean time since end of treatment was 8.3
Interventions Patients were treated with chemotherapy (n=20), BMT (n=3) and TBI (n=1)
Outcomes 1 patient (5.0%) had elevated GGT and 1 patient (5.0%) had elevated GGT and AST as well
Notes This study is written in Icelandic. At this moment we are awaiting the translation
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Thavaraj 2006
Methods Cohort study.
Participants 200 paediatric cancer survivors (165 boys, 35 girls) aged 1.3-30 years (mean 9.5) at follow-up with various tumours
Interventions 52 patients were treated with radiotherapy. Specific details on cancer treatment are not reported
Outcomes 14 patients had chronic liver disease and were HBsAntigen+ at a median follow-up of 2.5 years.
Notes This study has not been published in full text (as of February 2010), but has been presented at the SIOP conference
2006 (abstract PJ.032). From currently available data it is unclear if this study is eligible for inclusion in this review
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMT, bone marrow transplantation; GGT, gamma-glutamyl trans-
ferase; TBI, total body irradiation.
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D A T A A N D A N A L Y S E S
Comparison 1. Prevalence of hepatic late adverse effects




participants Statistical method Effect size
1 Prevalence of hepatic late adverse
effects in studies with an
outcome definition of ALT
above upper limit of normal
5 Prevalence (Random, 95% CI) Totals not selected
2 Prevalence of hepatic late adverse
effects in studies with an
outcome definition of ALT
above twice upper limit of
normal
3 Prevalence (Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Prevalence of hepatic late adverse effects, Outcome 1 Prevalence of hepatic
late adverse effects in studies with an outcome definition of ALT above upper limit of normal.
Review: Hepatic late adverse effects after antineoplastic treatment for childhood cancer
Comparison: 1 Prevalence of hepatic late adverse effects
Outcome: 1 Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT above upper limit of normal
Study or subgroup Prevalence (SE) Prevalence Prevalence
N N IV,Random,95% CI IV,Random,95% CI
Aric 1994 122 0 21.6 (4.07) 21.60 [ 13.62, 29.58 ]
Bessho 1994 25 0 8 (5.42) 8.00 [ -2.62, 18.62 ]
Bresters 2008 216 0 24.5 (2.93) 24.50 [ 18.76, 30.24 ]
Locasciulli 1997a 114 0 28.9 (4.25) 28.90 [ 20.57, 37.23 ]
Locasciulli 1997b 53 0 52.8 (6.86) 52.80 [ 39.35, 66.25 ]
-100 -50 0 50 100
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Analysis 1.2. Comparison 1 Prevalence of hepatic late adverse effects, Outcome 2 Prevalence of hepatic
late adverse effects in studies with an outcome definition of ALT above twice upper limit of normal.
Review: Hepatic late adverse effects after antineoplastic treatment for childhood cancer
Comparison: 1 Prevalence of hepatic late adverse effects
Outcome: 2 Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT above twice upper limit of normal
Study or subgroup Prevalence (SE) Prevalence Prevalence
N N IV,Random,95% CI IV,Random,95% CI
Bresters 2008 216 0 7.9 (1.84) 7.90 [ 4.29, 11.51 ]
Ratner 1986 39 0 23.1 (6.75) 23.10 [ 9.87, 36.33 ]
Rossetti 1991 96 0 44.8 (5.08) 44.80 [ 34.84, 54.76 ]
-100 -50 0 50 100
A D D I T I O N A L T A B L E S
Table 1. Risk of bias assessment criteria for observational studies
Internal validity External validity
Study group Selection bias (representative: yes/no)
• if the described study group consisted of more
than 90% of the original cohort of childhood cancer
survivors
• or if it was a random sample with respect to the
cancer treatment
Reporting bias (well defined: yes/no)
• if the type of chemotherapy and/or location of
radiotherapy was mentioned
• and if the number of patients with chronic viral
hepatitis was mentioned
Follow-up Attrition bias (adequate: yes/no)
• if the outcome was assessed for more than 90%
of the study group of interest (++)
• or if the outcome was assessed for 60-90% of the
study group of interest (+)
Reporting bias (well defined: yes/no)
• if the length of follow-up was mentioned
Outcome Detection bias (blind: yes/no)
• if the outcome assessors were blinded to the
investigated determinant
Reporting bias (well defined: yes/no)
• if the outcome definition was objective and
precise, i.e. if the upper limits of normal for liver
function tests were described in the definition of
hepatic late adverse effects
Risk estimation Confounding (adjustment for other factors: yes/no)
• if important prognostic factors (i.e. age, gender,
co-treatment) or follow-up were taken adequately into
account
Analyses (well defined: yes/no)
• if a relative risk, odds ratio, attributable risk,
linear or logistic regression model, mean difference or
Chi2 was calculated
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Table 2. Risk factors from univariate analyses that increase the risk of hepatic late adverse effects
Study Risk factor Significant (+/-)
Aricò 1994 Chronic HCV infection +
Ballauf 1999 Chronic HCV and HBV infection +
Bresters 2008 Older age at HSCT +
Bresters 2008 Diagnosis of benign haematological disease +
Bresters 2008 Gender -
Bresters 2008 HSCT donor type (matched sibling donor, other) -
Bresters 2008 Haematopoietic stem cell source (bone marrow,
autologous peripheral blood, cord blood)
-
Bresters 2008 Conditioning regimen (cyclophosphamide with
TBI/TAI, cyclophosphamide with busulphan,
other)
-
Bresters 2008 Early post-transplant morbidity (viral reactivation,
VOD, acute GVHD)
-
Chotsampancharoen 2009 Iron overload (high serum ferritin) +
Locasciulli 1983 Cleared or persistent chronic HBV infection +
Locasciulli 1983 Histological diagnosis of chronic hepatitis +
Locasciulli 1991a Chronic HCV infection +
Locasciulli 1997a Chronic HCV infection +
Rossetti 1991 Chronic HBV-HDV co-infection +
Rossetti 1991 Chronic HBV infection +
Tefft 1970 Site of radiotherapy (right lobe, left lobe, entire
liver, remaining liver)
-
Tefft 1970 Radiotherapy dose (<25 Gy, 25-35 Gy, >35 Gy) -
+, significant; -, not significant; GVHD, graft-versus-host disease; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D
virus; HSCT, haematopoietic stem cell transplantation; VOD, veno-occlusive disease.
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A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE (PubMed)
1. For hepatic late adverse effects the following MeSH headings and text words were used:
(liver fibrosis) OR (liver cirrhosis) OR (liver disease OR liver diseases OR liver diseas*) OR (liver dysfunction OR liver dysfunctions)
OR (liver damage) OR (liver failure) OR (liver enzyme[all fields] OR liver enzymes[all fields] OR (liver enzym*) OR (liver toxicity) OR
(liver disfunction) OR (radiation-induced liver disease OR radiation induced liver disease OR RILD) OR (liver function test OR liver
function tests) OR (liver insufficiency) OR (Hepatic Cirrhosis OR Cirrhoses, Hepatic OR Cirrhosis, Hepatic OR Hepatic Cirrhoses
OR Cirrhosis, Liver OR Cirrhoses, Liver OR Liver Cirrhoses OR Fibrosis, Liver OR Fibroses, Liver OR Liver Fibroses) OR (Disease,
Liver OR Diseases, Liver OR Dysfunction, Liver OR Dysfunctions, Liver OR Liver Dysfunctions) OR (Function Test, Liver OR
Function Tests, Liver OR Liver Function Test ORTest, Liver Function OR Tests, Liver Function) OR (Insufficiency, Hepatic OR Liver
Insufficiency OR Insufficiency, Liver) OR (hepatic dysfunction) OR (hepatic dysfunctions) OR (hepatic cirrhosis) OR (hepatic failure)
OR (hepatic function[all fields]) OR (liver function[all fields]) OR (radiation hepatitis) OR (hepatitis irradiation) OR (impaired liver
function) OR (hepatic fibrosis OR hepatic fibroses) OR (drug induced hepatitis) OR (toxic hepatitis) OR (hepatitides) OR (ASATOR
ALAT OR SGPT OR SGOT OR GGT) OR (alanine transaminase OR Transaminase, Alanine OR Glutamic-Alanine Transaminase
OR Glutamic Alanine Transaminase OR Transaminase, Glutamic-Alanine OR Alanine-2-Oxoglutarate OR Aminotransferase OR
Alanine 2 Oxoglutarate Aminotransferase OR Aminotransferase, Alanine-2-Oxoglutarate OR Alanine Aminotransferase OR Amino-
transferase, Alanine OR Glutamic-Pyruvic Transaminase OR Glutamic Pyruvic Transaminase OR Transaminase, Glutamic-Pyruvic)
OR (gamma Glutamyltransferase OR Glutamyl Transpeptidase OR Transpeptidase, Glutamyl OR GGTP OR gamma-Glutamyl
Transpeptidase OR Transpeptidase, gamma-Glutamyl OR gamma Glutamyl Transpeptidase OR gammaglutamyltransferase) OR (As-
partate Aminotransferases OR Aminotransferases, Aspartate OR Aspartate Apoaminotransferase OR Apoaminotransferase, Aspartate
ORAspartate Transaminase ORTransaminase, Aspartate ORGlutamic-Oxaloacetic Transaminase ORGlutamic Oxaloacetic Transam-
inase OR Transaminase, Glutamic-Oxaloacetic OR L-Aspartate-2-Oxoglutarate Aminotransferase OR Aminotransferase, L-Aspartate-
2-Oxoglutarate OR L Aspartate 2 Oxoglutarate Aminotransferase OR Aspartate Aminotransferase OR Aminotransferase, Aspartate
OR Glutamate-Aspartate Transaminase OR Glutamate Aspartate Transaminase OR Transaminase, Glutamate-Aspartate OR Serum
Glutamic-Oxaloacetic Transaminase OR Glutamic-Oxaloacetic Transaminase, Serum OR Serum Glutamic Oxaloacetic Transaminase
OR Transaminase, Serum Glutamic-Oxaloacetic) OR (hepatotoxicity OR hepatotoxic OR hepatotoxic*) OR (Veno-occlusive disease
OR VOD) OR (Veno occlusive disease) OR (hepatic veno-occlusive disease OR Disease, Hepatic Veno-Occlusive OR Hepatic Veno-
Occlusive Diseases OR Sinusoidal Obstruction Syndrome OR Syndrome, Sinusoidal Obstruction OR Hepatic Veno Occlusive Dis-
ease OR Veno-Occlusive Disease, Hepatic OR Veno Occlusive Disease, Hepatic) OR (iron overload OR hemosiderosis OR siderosis
OR heamosiderosis OR haemosiderosis) OR (Hemosideroses OR Overload, Iron) OR (bilirubin OR bilirubins OR bilirubin* OR
Bilirubin IX alpha OR Bilirubin, (4E)-Isomer OR Bilirubin, (4E,15E)-Isomer OR Hematoidin OR Bilirubin, Disodium Salt OR
Disodium Salt Bilirubin OR Bilirubin, Monosodium Salt ORMonosodium Salt Bilirubin OR delta-Bilirubin OR delta Bilirubin OR
Bilirubin, (15E)-Isomer OR Bilirubin, Calcium Salt OR Calcium Salt Bilirubin OR Salt Bilirubin, Calcium OR Calcium Bilirubinate
OR Bilirubinate, Calcium) OR (albumin OR albumins OR albumin*) OR (prothrombin OR prothrombins OR prothrombin*) OR
(Factor II OR Blood Coagulation Factor II OR Differentiation Reversal Factor OR Factor, Differentiation Reversal OR Coagulation
Factor II OR Factor II, Coagulation OR II, Coagulation Factor) OR (Alkaline phosphatase)
2. For survivors the following MeSH headings and text words were used:
Survivor OR survivors OR Long-Term Survivors OR Long Term Survivors OR Long-Term Survivor OR Survivor, Long-Term OR
Survivors, Long-Term OR survivo* OR surviving
3. For childhood cancer the following MeSH headings and text words were used:
(((leukemiaOR leukemi*OR leukaemi*OR (childhood ALL)ORAMLOR lymphomaOR lymphom*ORhodgkin ORhodgkin* OR
T-cell ORB-cell OR non-hodgkin OR sarcomaOR sarcom*OR sarcoma, Ewing’s OREwing* OR osteosarcomaOR osteosarcom*OR
wilms tumor OR wilms* OR nephroblastom* OR neuroblastoma OR neuroblastom* OR rhabdomyosarcoma OR rhabdomyosarcom*
OR teratoma OR teratom* OR hepatoma OR hepatom* OR hepatoblastoma OR hepatoblastom* OR PNET OR medulloblastoma
OR medulloblastom* OR PNET* OR neuroectodermal tumors, primitive OR retinoblastoma OR retinoblastom* OR meningioma
OR meningiom* OR glioma OR gliom*) OR (pediatric oncology OR paediatric oncology)) OR (childhood cancer OR childhood
tumor OR childhood tumors)) OR (brain tumor* OR brain tumour* OR brain neoplasms OR central nervous system neoplasm OR
central nervous system neoplasms OR central nervous system tumor* OR central nervous system tumour* OR brain cancer* OR brain
neoplasm* OR intracranial neoplasm*) OR (leukemia lymphocytic acute) OR (leukemia, lymphocytic, acute[mh])
The different searches were combined as 1 AND 2 AND 3.
[* = zero or more characters; mh = MeSH term]
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Appendix 2. Search strategy for EMBASE (Ovid)
1. For Hepatic late adverse effects the following Emtree terms and text words were used:
1. liver fibrosis.mp. or exp Liver Fibrosis/
2. (liver disease or liver diseases or liver diseas$).mp. or exp Liver Disease/
3. (liver dysfunction or liver dysfunctions or liver disfunction).mp. or exp Liver Dysfunction/
4. (hepatic dysfunction or hepatic dysfunctions or hepatic dysfunction$).mp.
5. (liver cirrhosis or liver cirrhoses).mp. or exp Liver Cirrhosis/
6. (hepatic cirrhosis or hepatic cirrhoses).mp.
7. (liver fibroses or hepatic fibrosis or hepatic fibroses).mp.
8. (liver damage or liver insufficiency or impaired liver function or hepatic insufficiency).mp.
9. exp Radiation Injury/ or (radiation induced liver disease or radiation-induced liver disease or RILD).mp.
10. (radiation hepatitis or hepatitis irradiation).mp.
11. drug induced hepatitis.mp. or exp Toxic Hepatitis/ or toxic hepatitis.mp. or hepatitides.mp.
12. liver failure.mp. or exp Liver Failure/
13. hepatic failure.mp.
14. liver enzyme.mp. or exp Liver Enzyme/
15. (liver enzymes or liver enzym$).mp.
16. hepatic function.mp. or exp Liver Function/
17. (liver function test or liver function tests.mp. or exp Liver Function Test/
18. liver toxicity.mp. or exp Liver Toxicity/
19. (hepatotoxicity or hepatotoxic or hepatotoxic$).mp.
20. (ASAT or ALAT or SGPT or SGOT or GGT).mp.
21. (Glutamic-Alanine Transaminase or Glutamic Alanine Transaminase).mp.
22. gamma Glutamyltransferase.mp. or exp Gamma Glutamyltransferase/
23. (Glutamyl Transpeptidase or GGTP or gamma-Glutamyl Transpeptidase or gamma Glutamyl Transpeptidase or gammaglutamyl-
transferase).mp.
24. (Alanine-2-Oxoglutarate or alanine transaminase).mp. or exp Alanine Aminotransferase/
25. (aspartate aminotransferases or aspartate aminotransferase).mp. or exp aspartate aminotransferase/
26. (aspartate apoaminotransferase or aspartate transaminase or glutamic-oxaloacetic transaminase or glutamic oxaloacetic transaminase
or L-aspartate-2-oxoglutarate aminotransferase or L aspartate 2 oxoglutarate aminotransferase or glutamate-aspartate transaminase or
glutamate aspartate transaminase).mp.
27. (Aminotransferase or Alanine 2 Oxoglutarate Aminotransferase).mp.
28. (alanine aminotransferase or serum glutamic-oxaloacetic transaminase or serum glutamic oxaloacetic transaminase).mp. or exp
Aspartate Aminotransferase Blood Level/
29. (Glutamic-Pyruvic Transaminase or Glutamic Pyruvic Transaminase).mp.
30. (veno-occlusive disease or veno occlusive disease).mp. or exp vein occlusion/
31. (VOD or hepatic veno-occlusive disease or hepatic veno-occlusive diseases or hepatic venoocclusive disease).mp. or exp Liver Vein
Obstruction/
32. sinusoidal obstruction syndrome.mp.
33. Iron overload.mp. or exp Iron Overload/
34. (hemosiderosis or siderosis or heamosiderosis or haemosiderosis or hemosideroses).mp. or exp Liver Hemosiderosis/ or exp siderosis/
35. (bilirubin or bilirubins or bilirubin$ or bilirubin IX alpha or hematoidin or disodium salt bilirubin or monosodium salt bilirubin
or delta-bilirubin or delta bilirubin or calcium salt bilirubin or calcium bilirubinate).mp. or exp Bilirubin/
36. (albumin or albumins or albumin$).mp. or exp Albumin/
37. exp Prothrombin/ or (prothrombin or prothrombins or prothrombin$ or factor II or blood coagulation factor II or differentiation
reversal factor or coagulation factor II).mp.
38. Alkaline phosphatase.mp. or exp Alkaline Phosphatase/
39. or/1-38
2. ForSurvivors the following Emtree terms and text words were used:
1. (survivor or survivors or (long adj term survivor) or (long adj term survivors) or survivo$).mp.
2. survivor/ or cancer survivor/
3. surviving.mp.
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4. 1 or 2 or 3
3. For Childhood cancer the following Emtree terms and text words were used:
1. (leukemia or leukemi$ or leukaemi$ or (childhood adj ALL) or acute lymphocytic leukemia).mp.
2. (AML or lymphoma or lymphom$ or hodgkin or hodgkin$ or T-cell or B-cell or non-hodgkin).mp.
3. (sarcoma or sarcom$ or Ewing$ or osteosarcoma or osteosarcom$ or wilms tumor or wilms$).mp.
4. (nephroblastom$ or neuroblastoma or neuroblastom$ or rhabdomyosarcoma or rhabdomyosarcom$ or teratoma or teratom$ or
hepatoma or hepatom$ or hepatoblastoma or hepatoblastom$).mp.
5. (PNET or medulloblastoma or medulloblastom$ or PNET$ or neuroectodermal tumors or primitive neuroectodermal tumor$ or
retinoblastoma or retinoblastom$ or meningioma or meningiom$ or glioma or gliom$).mp.
6. (pediatric oncology or paediatric oncology).mp.
7. ((childhood adj cancer) or (childhood adj tumor) or (childhood adj tumors) or childhoodmalignancy or (childhood adj malignancies)
or childhood neoplasm$).mp.
8. ((pediatric adj malignancy) or (pediatric adj malignancies) or (paediatric adj malignancy) or (paediatric adj malignancies)).mp.
9. ((brain adj tumor$) or (brain adj tumour$) or (brain adj neoplasms) or (brain adj cancer$) or brain neoplasm$).mp.
10. (central nervous system tumor$ or central nervous system neoplasm or central nervous system neoplasms or central nervous system
tumour$).mp.
11. intracranial neoplasm$.mp.
12. LEUKEMIA/ or LYMPHOMA/ or brain tumor/ or central nervous system tumor/ or teratoma/ or sarcoma/ or osteosarcoma/
13. nephroblastoma/ or neuroblastoma/ or rhabdomyosarcoma/ or hepatoblastoma/ or medulloblastoma/ or neuroectodermal tumor/
or retinoblastoma/ or meningioma/ or glioma/ or childhood cancer/
14. or/1-13
The different searches were combined as 1 AND 2 AND 3.
[mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name; /
= Emtree term; $ = zero or more characters]
Appendix 3. Search strategy for CENTRAL
1. For Hepatic late adverse effects the following text words were used:
(liver fibrosis OR liver cirrhosis OR liver disease OR liver diseases OR liver diseas* OR liver dysfunction OR liver dysfunctions
OR liver damage OR liver failure OR liver enzyme OR liver enzymes OR liver enzym* OR liver toxicity OR liver disfunction OR
radiation-induced liver disease OR radiation induced liver disease OR RILD OR liver function test OR liver function tests OR liver
insufficiency OR Hepatic Cirrhosis OR hepatic dysfunction OR hepatic dysfunctions OR hepatic cirrhosis OR hepatic failure OR
hepatic function OR liver function OR radiation hepatitis OR hepatitis irradiation OR impaired liver function OR hepatic fibrosis
OR hepatic fibroses OR drug induced hepatitis OR toxic hepatitis OR hepatitides OR ASAT OR ALAT OR SGPT OR SGOT OR
GGTOR alanine transaminase Glutamic-Alanine Transaminase OR Glutamic Alanine Transaminase OR Alanine-2-Oxoglutarate OR
Aminotransferase OR Alanine 2 Oxoglutarate Aminotransferase OR Alanine Aminotransferase OR Glutamic-Pyruvic Transaminase
OR Glutamic Pyruvic Transaminase OR gamma Glutamyltransferase OR Glutamyl Transpeptidase OR GGTP OR gamma-Glutamyl
Transpeptidase OR gamma Glutamyl Transpeptidase OR gammaglutamyltransferase OR Aspartate Aminotransferases OR Aspartate
ApoaminotransferaseORAspartateTransaminaseORGlutamic-OxaloaceticTransaminaseORGlutamicOxaloaceticTransaminaseOR
L-Aspartate-2-Oxoglutarate Aminotransferase OR L Aspartate 2 Oxoglutarate Aminotransferase OR Aspartate Aminotransferase OR
Glutamate-Aspartate Transaminase ORGlutamate Aspartate Transaminase OR SerumGlutamic-Oxaloacetic Transaminase OR Serum
Glutamic Oxaloacetic Transaminase OR hepatotoxicity OR hepatotoxic OR hepatotoxic* OR Veno-occlusive disease OR VOD OR
Veno occlusive disease OR hepatic veno-occlusive disease ORHepatic Veno-Occlusive Diseases OR Sinusoidal Obstruction Syndrome
OR Hepatic Veno Occlusive Disease OR iron overload OR hemosiderosis OR siderosis OR heamosiderosis OR haemosiderosis OR
Hemosideroses OR bilirubin OR bilirubins OR bilirubin* OR Bilirubin IX alpha OR Hematoidin OR Disodium Salt Bilirubin OR
Monosodium Salt Bilirubin OR delta-Bilirubin OR delta Bilirubin OR Calcium Salt Bilirubin OR Calcium Bilirubinate OR albumin
OR albumins OR albumin* OR prothrombin OR prothrombins OR prothrombin* OR Factor II OR Blood Coagulation Factor II
OR Differentiation Reversal Factor OR Coagulation Factor II OR Alkaline phosphatase)
2. For Survivors the following text words were used:
(Survivor OR survivors OR Long-Term Survivors OR Long Term Survivors OR Long-Term Survivor OR survivo* OR surviving)
3. For Childhood cancer the following text words were used:
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(leukemia OR leukemi* OR leukaemi* OR childhood ALL OR AML OR lymphoma OR lymphom* OR hodgkin OR hodgkin* OR
T-cell OR B-cell OR non-hodgkin OR sarcoma OR sarcom* OR Ewing* OR osteosarcoma OR osteosarcom* OR wilms tumor OR
wilms* OR nephroblastom*OR neuroblastoma OR neuroblastom*OR rhabdomyosarcoma OR rhabdomyosarcom*OR teratoma OR
teratom*ORhepatomaORhepatom*ORhepatoblastomaORhepatoblastom*ORPNETORmedulloblastomaORmedulloblastom*
OR PNET* OR neuroectodermal tumors, primitive OR retinoblastoma OR retinoblastom* OR meningioma OR meningiom* OR
glioma OR gliom* OR pediatric oncology OR paediatric oncology OR childhood cancer OR childhood tumor OR childhood tumors
OR brain tumor* OR brain tumour* OR brain neoplasms OR central nervous system neoplasm OR central nervous system neoplasms
OR central nervous system tumor* OR central nervous system tumour* OR brain cancer* OR brain neoplasm* OR intracranial
neoplasm OR acute lymphocytic leukemia)
The different searches were combined as 1 AND 2 AND 3.
The search will be performed in title, abstract or keywords.
[* =zero or more characters]
WH A T ’ S N E W
Last assessed as up-to-date: 21 December 2009.
Date Event Description
29 January 2015 Amended Contact details updated.
C O N T R I B U T I O N S O F A U T H O R S
Renée Mulder designed the study and wrote the protocol. She identified the studies meeting the inclusion criteria (both by initial
screening and thereafter). She searched for unpublished and ongoing studies; performed the data extraction and the risk of bias
assessment of the included studies; analysed the data and interpreted the results. She wrote and revised the manuscript.
Elvira van Dalen designed the study and critically reviewed the protocol. She identified studies meeting the inclusion criteria and
contributed to the interpretation of the results. She critically reviewed the manuscript.
Malon Van den Hof performed the data extraction and the risk of bias assessment of the included studies. She analysed the data and
interpreted the results.
Dorine Bresters critically reviewed the protocol. She identified studies meeting the inclusion criteria. She critically reviewed the
manuscript.
Bart Koot critically reviewed the protocol. He identified studies meeting the inclusion criteria and contributed to the interpretation of
the results. He critically reviewed the manuscript.
Sharon Castellino critically reviewed the manuscript.
Yoon Loke critically reviewed the protocol and the manuscript.
Edith Leclercq developed the search strategy. She critically reviewed the protocol and identified studies meeting the inclusion criteria.
She critically reviewed the manuscript.
Piet Post critically reviewed the protocol. He identified studies meeting the inclusion criteria. He critically reviewed the manuscript.
Huib Caron critically reviewed the protocol and the manuscript.
Aleida Postma critically reviewed the protocol. She identified studies meeting the inclusion criteria. She critically reviewed the
manuscript.
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Leontien Kremer designed the study and critically reviewed the protocol. She identified studies meeting the inclusion criteria and
contributed to the interpretation of the results. She critically reviewed the manuscript.
All authors approved the final version.
D E C L A R A T I O N S O F I N T E R E S T
Dorine Bresters is an author of a study included in this systematic review.
S O U R C E S O F S U P P O R T
Internal sources
• Dutch Cochrane Centre, Netherlands.
External sources
• Foundation of Paediatric Cancer Research (SKK), Netherlands.
• Stichting Kinderen Kankervrij (KiKa), Netherlands.
• Dr Castellino is supported in part by a grant from the U.S. National Institutes of Health R25 CA122061, USA.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the title of this systematic review. The title of the protocol was ’Hepatic late adverse effects after treatment for childhood
cancer’. The new title is ’Hepatic late adverse effects after antineoplastic treatment for childhood cancer’.
In the protocol it was stated that all study designs, except case reports and case series, examining the effect of treatment for childhood
cancer on hepatic late adverse effects would be included. However, we also excluded studies including less than 10 patients.
In addition, in the protocol it was stated that studies with a maximum follow-up of one year or less would be excluded and if no follow-
up time after the end of treatment was stated more than 90% of the study group should have been off treatment. However, we decided
to only include studies in which more than 50% of the study group was off treatment for at least one year to assure that we would
analyse late adverse effects and not acute toxicity.
Also, we adapted the risk of bias assessment criteria for an adequate follow-up and a well defined outcome. The definition of a low
risk of follow-up bias was as follows: if the outcome was assessed at the end date of the study for 60% to 90% of the study group or if
the outcome was assessed for more than 90% of the study group but with an unknown end date. Since there is not a straightforward
definition for the end date of the study, we decided to change this risk of bias item. The new definition of a low risk of follow-up bias
is as follows: if the outcome was assessed for more than 90% of the study group of interest (++) or if the outcome was assessed for
60% to 90% of the study group of interest (+). In the protocol we had not yet specified the definition of a well defined outcome. The
definition is as follows: if the outcome definition was objective and precise, that is if the upper limits of normal for liver function tests
were described in the definition of hepatic late adverse effects.
Since we were able to perform the analysis using RevMan we did not need the statistical software Comprehensive Meta Analysis.
Finally, in the protocol it was stated that we planned to conduct a multivariate linear meta-regression analysis to examine the relation
between potential predictive factors and hepatic late adverse effects. Because studies lacked important data on potential predictive
factors (that is treatment characteristics, age at diagnosis, age at treatment) we were not able to perform this analysis.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Alanine Transaminase [metabolism]; Antineoplastic Agents [∗adverse effects]; Chemical and Drug Induced Liver Injury [∗etiology];
Cohort Studies; Hepatitis, Viral, Human [complications]; Liver [drug effects]; Neoplasms [∗drug therapy]
MeSH check words
Child; Humans
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